{
    "K143467.txt": {
        "deviceName": "FORA GD43 Blood Glucose Meter",
        "intendedUse": "The FORA GD43 Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood from the fingertip and alternative sites (palm, forearm and upper arm).",
        "predicateDevice": "FORA GD40 Blood Glucose Monitoring System",
        "indicationsForUse": "The FORA GD43 Blood Glucose Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control.",
        "testPrinciple": "The test is based on the measurement of electrical current generated by the reaction of glucose with the reagent of the strip.",
        "analyticalSpecificity": "The FORA GD43 Blood Glucose Monitoring System has limitations due to potential interference from certain substances such as dopamine, L-Dopa, methyldopa, tolazamide, ascorbic acid (vitamin C), acetaminophen and mannose.",
        "submissionType": "New device",
        "specialConditionsForUse": "For in vitro diagnostic use only, Not for use in diagnosis or screening of diabetes mellitus, Not for neonatal use, Not for use on patients who are dehydrated, hypotensive, in shock, or for individuals in hyperglycemic-hyperosmolar state, with or without ketosis.",
        "deviceDescription": "The FORA GD43 Blood Glucose Monitoring System consists of the FORA GD43 Blood Glucose Meter, Owner\u2019s Manual, Protective Wallet, Quick Start User Guide, Daily Log Book, Warranty Card and 2 x 1.5 V AAA alkaline batteries.",
        "regulatoryInformation": "Class II, 21 CFR 862.1345, Glucose test system, Product code: NBW, System, Test, Blood Glucose, Over the Counter, LFR, Glucose Dehydrogenase, Glucose"
    },
    "K171742.txt": {
        "deviceName": "N Latex FLC Kappa and N Latex FLC Lambda assays",
        "intendedUse": "In-vitro diagnostic reagents for the quantitative determination of free light chains (FLC), type kappa or type lambda in human serum and EDTA-plasma by means of particle-enhanced immunonephelometry using the BN Systems",
        "predicateDevice": "The Binding Site Freelite Human Kappa Free Kit for use on the Siemens BN II - K031016, The Binding Site Freelite Human Lambda Free Kit for use on the Siemens BN II - K031016",
        "indicationsForUse": "Aid in the diagnosis of multiple myeloma (MM) and amyloidosis (AL)",
        "testPrinciple": "Particle-enhanced immunonephelometry",
        "analyticalSpecificity": "No interferences were observed with the following tabulated lists of endogenous and exogenous substances",
        "submissionType": "510(k) Substantial Equivalence Determination",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The N Latex FLC Kappa and N Latex FLC Lambda assays are comprised of the following reagents in liquid form: N latex FLC reagents",
        "regulatoryInformation": "Class II, test systems, 21 CFR \u00a7 866.5550 \u2013 Immunoglobulin (light chain specific) immunological test system, 21 CFR \u00a7 862.1660 \u2013 Quality Control Material (assayed and unassayed)"
    },
    "K170491.txt": {
        "deviceName": "Solana C. difficile Assay",
        "intendedUse": "The Solana C. difficile assay is an in vitro diagnostic test for the direct, qualitative detection of the Clostridium difficile Toxin A gene (tcdA) in unformed stool specimens of patients suspected of having Clostridium difficile infection (CDI).",
        "predicateDevice": "Portrait Toxigenic C. difficile Assay",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "A small amount of specimen is transferred to a Lysis Tube using a swab. The Lysis Tube is then subjected to heat\u2010treatment at 95 \u00b0C for five minutes. The heat\u2010treated sample is added to a Dilution Tube, and then transferred to a Reaction Tube.",
        "analyticalSpecificity": "The analytical specificity of the Solana C. difficile Assay was evaluated by testing a panel of sixty\u2010eight bacterial, viral and yeast microorganisms and human DNA representing enteric pathogens, flora or nucleic acids commonly present in the intestine.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only, For in vitro diagnostic use only",
        "deviceDescription": "The Solana C. difficile Assay combines sample processing and Helicase\u2010Dependent Amplification (HDA) performed in the Solana instrument for the detection of toxigenic Clostridium difficile directly from CDI\u2010suspected diarrheal specimens.",
        "regulatoryInformation": "21 CFR 866.3130, Clostridium difficile toxin gene amplification assay"
    },
    "K161220.txt": {
        "deviceName": "ARIES Flu A/B & RSV Assay",
        "intendedUse": "The ARIES Flu A/B & RSV Assay is a polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection and differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) nucleic acid in nasopharyngeal swab (NPS) specimens from patients with signs and symptoms of respiratory tract infection in conjunction with clinical and laboratory findings.",
        "predicateDevice": "Simplexa Flu A/B & RSV Direct",
        "indicationsForUse": "The ARIES Flu A/B & RSV Assay is indicated for use with the ARIES Systems.",
        "testPrinciple": "The ARIES Flu A/B & RSV Assay chemistry is based on an expanded genetic alphabet technology, consisting of synthetic DNA base pair 2'-deoxy-5-methyl-isocytidine (iC): 2'-deoxyisoguanosine (iG).",
        "analyticalSpecificity": "The analytical specificity of the ARIES Flu A/B and RSV Assay was evaluated against twenty-four influenza A strains, seven influenza B strains, and three respiratory syncytial virus (RSV) strains, which differ from those strains included in the LoD study.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "Prescription use only",
        "deviceDescription": "The ARIES Flu A/B & RSV Assay is a polymerase chain reaction (PCR)-based qualitative in vitro diagnostic test system that consists of the ARIES Systems with its included software, an assay-specific cassette, and an assay-specific protocol file.",
        "regulatoryInformation": "The ARIES Flu A/B & RSV Assay is classified as a Class II device under 21 CFR 866.3980, Respiratory viral panel multiplex nucleic acid assay, with product codes OCC, OOI, and OZE."
    },
    "K172913.txt": {
        "deviceName": "cobas Factor II and Factor V Test",
        "intendedUse": "The cobas Factor II and Factor V Test is an in vitro diagnostic device that uses real-time PCR for the detection and genotyping of the Factor II (Prothrombin) G20210A mutation and the Factor V Leiden G1691A mutation in genomic DNA obtained from K2EDTA whole blood specimens as an aid in diagnosis of patients with suspected thrombophilia.",
        "predicateDevice": "Roche Factor II (Prothrombin) G20210A Kit and Roche Factor V Leiden Kit",
        "indicationsForUse": "Aid in the diagnosis of patients with suspected thrombophilia",
        "testPrinciple": "Real-time PCR test for simultaneous amplification of two targets and detection of specific SNPs in the PCR amplified DNA sequences (multiplex system)",
        "analyticalSpecificity": "The test can detect and genotype the Factor II (Prothrombin) G20210A mutation and the Factor V Leiden G1691A mutation in genomic DNA obtained from K2EDTA whole blood specimens",
        "submissionType": "510(k) submission",
        "specialConditionsForUse": "Prescription Use only",
        "deviceDescription": "The cobas Factor II and Factor V Test is a real-time polymerase chain reaction (PCR) test for the qualitative detection and genotyping of a single point mutation in the human Factor V gene (G to A at position 1691, referred to as the Factor V Leiden mutation) and a single point mutation in the human Factor II gene (G to A at position 20210)",
        "regulatoryInformation": "Class II, Product code: NPR; Test, Factor II G20210A Mutations, Genomic DNA PCR, Factor V Leiden DNA Mutation Detection Systems and NPQ; Test, Factor V Leiden Mutations, Genomics DNA PCR, Factor V Leiden DNA Mutation Detection Systems"
    },
    "K160082.txt": {
        "deviceName": "Puritan Opti-Tranz Cary-Blair Collection and Transport System",
        "intendedUse": "The Puritan Opti-Tranz Cary-Blair Collection and Transport System is intended for use in the collection and transport of clinical fecal and rectal swab specimens to preserve the viability of enteric bacteria during transport from the collection site to the testing laboratory for bacteriological examination and culture.",
        "predicateDevice": "Copan Venturi Transystem Cary-Blair Medium product (132C)",
        "indicationsForUse": "Same as intended use",
        "testPrinciple": "Not applicable",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "Puritan Opti-Tranz Cary-Blair Collection and Transport System is comprised of a peel pouch containing a rayon tipped swab applicator for collecting specimens and a polypropylene, round-bottomed, capped tube containing 5 ml of a semi-solid Cary-Blair medium",
        "regulatoryInformation": "Class I, Product code: JSM; Culture Media, Non-Propagating Transport, LIO: Device, Specimen Collection, JTW: System, Transport, Aerobic, 866.2390; Transport Culture Medium"
    },
    "K180886.txt": {
        "deviceName": "Liofilchem MIC Test Strip (MTS), Delafloxacin 0.002-32 \u03bcg/mL",
        "intendedUse": "The Liofilchem MIC Test Strip (MTS) is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria.",
        "predicateDevice": "Liofilchem MTS, vancomycin",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "MTS are made of specialized paper impregnated with a predefined concentration gradient of antibiotic, across 15 two-fold dilutions similar to dilutions used by conventional MIC methods.",
        "analyticalSpecificity": "Not Applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use. The ability of the Liofilchem MIC Test Strip (MTS) to detect resistant isolates with the following drug/bacterial species combinations is unknown because resistant isolates were either not available or an insufficient number was encountered at the time of comparative testing.",
        "deviceDescription": "The Delafloxacin MIC Test Strip (MTS) consists of specialized paper impregnated with a predefined concentration gradient of Delafloxacin across 15 two-fold dilutions similar to dilutions used by conventional MIC methods.",
        "regulatoryInformation": "Regulation section: 866.1640 Antimicrobial Susceptibility Test Powder, Classification: II, Product code: JWY - Manual Antimicrobial Susceptibility Test Systems, Panel: 83 \u2013 Microbiology"
    },
    "K153278.txt": {
        "deviceName": "iHealth Wireless Smart Gluco-Monitoring System (BG5)",
        "intendedUse": "The iHealth Wireless Gluco-Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip, palm, forearm, upper arm, calf, or thigh.",
        "predicateDevice": "iHealth BG5 Wireless Smart Gluco-Monitoring System (k123935)",
        "indicationsForUse": "The iHealth Wireless Gluco-Monitoring System is intended to be used by a single person and should not be shared. The iHealth Wireless Gluco-Monitoring System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control.",
        "testPrinciple": "The iHealth Wireless Smart Gluco-Monitoring System (BG5) measures glucose amperometrically. The reaction of glucose oxidase and an electron mediator in the test strip with glucose in the sample produces an electrical current which is proportional to the amount of glucose in the sample.",
        "analyticalSpecificity": "The sponsor performed interference studies with spiked venous blood samples at three glucose concentrations (~80, 120, and 350 mg/dL) that were prepared and divided into a test (dosed) pool and a control pool.",
        "submissionType": "Modified devices to add compatibility with Android mobile platforms",
        "specialConditionsForUse": "Not for use in critically ill patients, The iHealth system is not intended for use on neonates, The iHealth system is not intended for use on arterial blood, serum, or plasma",
        "deviceDescription": "The iHealth Wireless Smart Gluco-Monitoring System (BG5) consists of the iHealth Wireless Smart blood glucose meter (BG5), AGS 1000I Test Strips, sterile lancets, lancing device and the iHealth control solutions.",
        "regulatoryInformation": "Regulation Name: Glucose test system, Class: II, Product Code: NBW, Panel: (75) Chemistry"
    },
    "K181525.txt": {
        "deviceName": "INNOVANCE Free PS Ag",
        "intendedUse": "For the quantitative determination of free protein S antigen in human plasma collected from venous blood samples in 3.2% sodium citrate tubes on the Sysmex CS-5100 analyzer. As an aid in the diagnosis of protein S deficiency in patients who are suspected of free protein S deficiency.",
        "predicateDevice": "STA-Liatest Free Protein S",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "Immunoturbidimetry",
        "analyticalSpecificity": "The INNOVANCE Free PS Ag assay has been evaluated for potential interference from various endogenous and exogenous substances and showed no significant interference up to the specified concentrations.",
        "submissionType": "New Device",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The INNOVANCE Free PS Ag assay is an immunoturbidimetric assay consisting of a reagent and buffer. The reagent contains polystyrene particles coated with two different monoclonal mouse antibodies specific for free protein S.",
        "regulatoryInformation": "21 CFR 864.7290, Factor deficiency test, Class II, Product code: GGP, Test, qualitative and quantitative factor deficiency, Panel: Hematology (81)"
    },
    "K190223.txt": {
        "deviceName": "Cepheid Xpert CT/NG Control Panel",
        "intendedUse": "The Cepheid Xpert CT/NG Control Panel is intended for use as an external assayed positive and negative quality control to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) performed with the Cepheid Xpert CT/NG assay on the GeneXpert Instrument System.",
        "predicateDevice": "Cepheid Xpert GBS LB Control Panel",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "Not applicable; this is control material to monitor performance of an in vitro diagnostic test.",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For in vitro diagnostic use only. For prescription use only.",
        "deviceDescription": "The Cepheid Xpert CT/NG Control Panel is a quality control material provided to the customer as six individually packaged positive and negative swabs.",
        "regulatoryInformation": "Class II (Special Controls), 21 CFR 866.3920, Assayed quality control material for clinical microbiology assays"
    },
    "K162042.txt": {
        "deviceName": "OptiScanner 5000 Glucose Monitoring System",
        "intendedUse": "The OptiScanner 5000 Glucose Monitoring System is an automated, bedside glucose monitoring device indicated for detecting trends and tracking patterns in persons (age 18 and older) in the surgical intensive care unit.",
        "predicateDevice": "VIA Medical Corp Pump/Blood Chemistry Monitor",
        "indicationsForUse": "The OptiScanner 5000 Glucose Monitoring System is indicated for use in determining dysglycemia.",
        "testPrinciple": "The OptiScanner 5000 Glucose Monitoring System samples and measures blood glucose levels every 15 minutes using mid-infrared (MIR) light (7 um \u2013 10 um wavelength) absorption spectra through an array of optical filters.",
        "analyticalSpecificity": "Fifty-two endogenous and exogenous substances were evaluated in a bench study to determine the effect of potentially interfering compounds on device performance.",
        "submissionType": "New device",
        "specialConditionsForUse": "Prescription use only. Contraindications: Patients that are <18 years of age, Women who are pregnant or nursing, Patients undergoing Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT)",
        "deviceDescription": "The OptiScanner 5000 Glucose Monitoring System is comprised of the OptiScanner 5000 Instrument, a transportation cart, disposable OptiScanner cartridges, and a barcode scanner with USB connectivity.",
        "regulatoryInformation": "Product Code: LZF, Classification: II, Regulation: 21 CFR \u00a7880.5725, Panel: General Hospital"
    },
    "K171770.txt": {
        "deviceName": "cobas Liat System",
        "intendedUse": "The cobas Cdiff Nucleic acid test for use on the cobas Liat System is an automated, qualitative in vitro diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the detection of the toxin B (tcdB) gene of toxigenic Clostridium difficile in unformed (liquid or soft) stool specimens obtained from patients suspected of having C. difficile infection (CDI).",
        "predicateDevice": "cobas Cdiff Test for use on the cobas 4800 System",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "The cobas Liat Cdiff test uses silica magnetic particle-based nucleic acid extraction and TaqMan probe-based real-time PCR amplification and detection.",
        "analyticalSpecificity": "The test has been evaluated for cross-reactivity with 117 bacteria, fungi, and viruses, as well as 29 Clostridium genus organisms, and has shown no interference with detection of the intended toxigenic C. difficile targets.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only. The assay has only been validated for use with unformed or partially formed stool specimens that have been transferred into the cobas PCR Media tube according to the Instructions For Use.",
        "deviceDescription": "The cobas Cdiff Nucleic acid test for use on the cobas Liat System (cobas Liat Cdiff) is a rapid, automated in vitro diagnostic test for the qualitative detection of C. difficile DNA in human stool specimens.",
        "regulatoryInformation": "21 CFR 866.3130, Clostridium difficile toxin gene amplification assay"
    },
    "K171641.txt": {
        "deviceName": "Accula Flu A/Flu B Test",
        "intendedUse": "The Accula Flu A/Flu B Test performed on the Accula Dock is a molecular in vitro diagnostic test utilizing polymerase chain reaction (PCR) and lateral flow technologies for the qualitative, visual detection and differentiation of influenza A and influenza B viral RNA.",
        "predicateDevice": "Alere i Influenza A&B",
        "indicationsForUse": "The Accula Flu A/Flu B Test is intended as an aid in the diagnosis of influenza infection in conjunction with clinical and epidemiological risk factors.",
        "testPrinciple": "Nucleic acid amplification plus hybridization to a membrane and chromatographic visual detection",
        "analyticalSpecificity": "No cross-reactivity was observed for any of the microorganisms tested",
        "submissionType": "510(k) and CLIA waiver package for dual review",
        "specialConditionsForUse": "For Prescription Use",
        "deviceDescription": "The Accula Flu A/Flu B Test is a semi-automated, colorimetric, multiplex reverse-transcription polymerase chain reaction (RT-PCR) nucleic acid amplification test to qualitatively detect influenza A and B viral RNA from unprocessed nasal swabs",
        "regulatoryInformation": "Class II, 21 CRF 866.3980, Respiratory viral panel multiplex nucleic acid assay, Product code: OZE - Influenza A and Influenza B Multiplex Nucleic Acid Assay"
    },
    "K180559.txt": {
        "deviceName": "HSV 1&2 ELITe MGB Assay",
        "intendedUse": "The HSV 1&2 ELITe MGB Assay is a real-time polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection and differentiation of Herpes Simplex Virus 1 and 2 (HSV-1 and HSV-2) DNA in cutaneous or mucocutaneous lesion swab specimens from patients with signs and symptoms of HSV-1 or HSV-2 infection.",
        "predicateDevice": "ARIES HSV 1&2 Assay",
        "indicationsForUse": "Same as intended use",
        "testPrinciple": "The HSV 1&2 ELITe MGB Assay system is comprised of three major processes: automated preparation of unprocessed sample to extract nucleic acids from primary swab specimens, PCR amplification of target DNA sequences using HSV-1 and HSV-2 specific primers, and real-time detection of fluorescent-labeled HSV-1 and HSV-2 specific oligonucleotide detection probes.",
        "analyticalSpecificity": "The analytical specificity of the HSV 1&2 ELITe MGB Assay was evaluated by testing 49 different microbial species that are either genetically related to HSV1 and HSV2 or cause similar clinical symptoms or may be present in the cutaneous and mucocutaneous sites tested by this device.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The HSV 1&2 ELITe MGB Assay is a multiplexed qualitative in vitro diagnostic Real-Time PCR Assay that uses unique primer sets and single uniquely labeled probes to amplify and detect the Herpes Simplex Virus genotype 1 and the HSV-2 glycoprotein G encoding gene.",
        "regulatoryInformation": "Class II, 21CFR 866.3309, Product code: PGI, Panel: 83 - Microbiology"
    },
    "K160538.txt": {
        "deviceName": "Sysmex XN-L Automated Hematology Analyzer",
        "intendedUse": "in vitro diagnostic use in screening patient populations found in clinical laboratories",
        "predicateDevice": "Sysmex XN-Series (XN-10, XN-20) Automated Hematology Analyzer",
        "indicationsForUse": "The XN-L analyzer classifies and enumerates the following parameters in whole blood: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT, NEUT%/#, LYMPH%/#, MONO%/#, EO%/#, BASO%/#, IG%/#, RDW-CV, RDW-SD, MPV, RET%/#, IRF, RET-He and has a Body Fluid mode for body fluids",
        "testPrinciple": "Performs hematology analyses according to the Hydro Dynamic Focusing (DC Detection), flow cytometry method (using a semiconductor laser), and SLS hemoglobin method",
        "analyticalSpecificity": "The XN-L analyzer automatically classifies cells from whole blood and body fluids and carries out all processes automatically from aspiration of the sample to result output",
        "submissionType": "510(k) Number: K160538",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The Sysmex XN-L analyzer is a quantitative multi-parameter automated hematology analyzer",
        "regulatoryInformation": "Class II, 21 CFR 864.5220, Automated differential cell counter"
    },
    "K151923.txt": {
        "deviceName": "VITEK 2 AST-Yeast Micafungin",
        "intendedUse": "The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp. and clinically significant yeast.",
        "predicateDevice": "VITEK 2 AST-YS Flucytosine",
        "indicationsForUse": "VITEK 2 Yeast Micafungin is designed for antifungal susceptibility testing of Candida species.",
        "testPrinciple": "The VITEK 2 System optics use visible light to directly measure organism growth.",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The VITEK 2 AST card is a miniaturized, abbreviated and automated version of the doubling dilution technique for determining the minimum inhibitory concentration (MIC).",
        "regulatoryInformation": "21 CFR 866.1640, Antimicrobial Susceptibility Test Powder"
    },
    "K182472.txt": {
        "deviceName": "Cepheid Xpert GBS LB Control Panel",
        "intendedUse": "The Cepheid Xpert GBS LB Control Panel is intended for use as external assayed positive and negative quality control materials to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Group B Streptococcus (GBS) performed with the Cepheid Xpert GBS LB Assay on the GeneXpert Instrument System.",
        "predicateDevice": "Bio-Rad Amplichek II",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "The Cepheid Xpert GBS LB Control Panel is intended for use as external assayed quality control materials for use in monitoring the DNA extraction, amplification and detection processes associated with the Cepheid Xpert GBS LB Assay (K121539) on the GeneXpert Instrument System.",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For in vitro diagnostic use only. For prescription use only. This product is not intended to replace the manufacturer controls provided with the Cepheid Xpert GBS LB Assay.",
        "deviceDescription": "The Cepheid Xpert GBS LB Control Panel (Assayed Microbiology Control) is used to monitor DNA extraction, amplification and detection by the Cepheid Xpert GBS LB Assay on the GeneXpert Instrument System.",
        "regulatoryInformation": "21 CFR 866.3920: Assayed quality control material for clinical microbiology assays, Class II (Special Controls)"
    },
    "K162688.txt": {
        "deviceName": "Sysmex CS-2100i",
        "intendedUse": "The Sysmex CS-2100i is a fully automated blood coagulation analyzer intended for in vitro diagnostic use using plasma collected from venous blood samples in 3.2% sodium citrate tubes to analyze clotting, chromogenic and immunoassay methods in the clinical laboratory.",
        "predicateDevice": "Sysmex Automated Coagulation Analyzer CA-1500",
        "indicationsForUse": "Same as Intended Use(s) above",
        "testPrinciple": "Coagulation Factor V and Coagulation Factor VII with Dade Innovin: Factor activity is determined by mixing and incubation of diluted patient plasma with factor V or VII deficient plasma and Dade Innovin Reagent prepared from purified recombinant human tissue factor, combined with synthetic phospholipids (thromboplastin), calcium, buffers and stabilizers.",
        "analyticalSpecificity": "Interference with hemoglobin, conjugated and unconjugated bilirubin and triglycerides was tested for each assay.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The Sysmex CS-2100i is a standalone automated blood coagulation analyzer which analyzes venous plasma samples collected in 3.2% sodium citrate using clotting, chromogenic and immunoassay methods.",
        "regulatoryInformation": "Class II, 21 CFR 864.5425, Multipurpose system for in vitro coagulation studies"
    },
    "K190332.txt": {
        "deviceName": "Aperio AT2 DX System",
        "intendedUse": "The Aperio AT2 DX System is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue.",
        "predicateDevice": "Philips IntelliSite Pathology Solution (PIPS)",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "The Aperio AT2 DX System is an automated system designed for scanning and digitizing surgical pathology slides prepared from FFPE tissue.",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For in vitro diagnostic (IVD) use only, For prescription use only",
        "deviceDescription": "The Aperio AT2 DX System is an automated digital slide creation and viewing system.",
        "regulatoryInformation": "21 CFR 864.3700, Class II (special controls), Product code: PSY, Panel: 88 - Pathology"
    },
    "K151046.txt": {
        "deviceName": "illumigene HSV 1&2 DNA Amplification Assay",
        "intendedUse": "The illumigene HSV 1&2 DNA amplification assay, performed on the illumipro-10, is a qualitative in vitro diagnostic test for the direct detection and differentiation of herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) DNA in cutaneous and mucocutaneous lesion specimens from male and female patients suspected of Herpetic infections.",
        "predicateDevice": "Lyra Direct HSV 1 + 2/VZV assay (Quidel Corporation)",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "The illumigene HSV 1&2 assay is based on loop mediated isothermal amplification technology (LAMP). Loop mediated amplification of DNA is accomplished by the use of specially designed primers that provide specific and continuous isothermal amplification.",
        "analyticalSpecificity": "None of the following organisms or their genetic material reacted with the illumigene HSV 1&2 DNA Amplification Assay: Acinetobacter calcoaceticus, Acinetobacter lwoffii, Bacteroides fragilis, Bordetella bronchiseptica, Bordetella pertussis, Candida albicans, Candida glabrata, Candida guilliermondii, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Chlamydia trachomatis, Chlamydophila pneumoniae, Clostridium difficile, Clostridium perfringens, Corynebacterium diphtheriae, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli (ESBL), Fusobacterium nucleatum, Gardnerella vaginalis, Haemophilus ducreyi, Haemophilus influenzae (Type A), Klebsiella pneumoniae, Lactobacillus acidophilus, Legionella pneumophila, Mobiluncus curtisii, Mobiluncus mulieris, Moraxella catarrhalis, Mycoplasma hominis, Mycoplasma orale, Mycoplasma pneumoniae, Mycoplasma salivarium, Neisseria gonorrhoeae, Neisseria meningitidis, Prevotella melaninogenica, Proteus mirabilis, Pseudomonas aeruginosa, Salmonella enteritidis, Salmonella typhimurium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus mitis, Streptococcus mutans, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus salivarius, Toxoplasma gondii, Treponema palladium, Trichomonas vaginalis, Ureaplasma urealyticum, Adenovirus, Coronavirus, Coxsackievirus, Cytomegalovirus, Echovirus, Enterovirus, Epstein Barr virus, Influenza A virus, Influenza B virus, Hepatitis B virus, Hepatitis C virus, Human herpes 6 virus, Human herpes 7 virus, Human herpes 8 virus, Human immunodeficiency virus type 1, Human metapneumovirus, Human papilloma virus, Measles virus, Mumps virus, Parainfluenza virus, Respiratory syncytial virus, Rubella virus, Varicella zoster virus.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only.",
        "deviceDescription": "The illumigene Molecular Diagnostic Test System is comprised of the illumigene HSV 1&2 DNA Amplification Assay Test Kit, the illumigene HSV 1&2 External Control Kit, and the illumipro-10 Automated Isothermal Amplification and Detection System.",
        "regulatoryInformation": "Regulation section: 21 CFR 866.3309, Classification: Class II, Product code: PGI, Panel: Microbiology (83)"
    },
    "K172333.txt": {
        "deviceName": "Sysmex Automated Blood Coagulation Analyzer CS-5100",
        "intendedUse": "The Sysmex CS-5100 is a fully automated blood coagulation analyzer intended for in vitro diagnostic use using plasma collected from venous blood samples in 3.2% sodium citrate tubes to analyze clotting, chromogenic and immunoassay methods in the clinical laboratory.",
        "predicateDevice": "Sysmex CA-1500",
        "indicationsForUse": "For determination of: Prothrombin Time (PT) seconds and PT INR with Dade Innovin; Activated Partial Thromboplastin Time (APTT) with Dade Actin FSL; Fibrinogen (Fbg) with Dade Thrombin Reagent; Coagulation Factor V with Dade Innovin; Coagulation Factor VII with Dade Innovin; Coagulation Factor VIII with Dade Actin FSL; Coagulation Factor IX with Dade Actin FSL; Lupus Anticoagulant with LA1 Screening and LA2 Confirmation Reagent; Factor V Leiden with Factor V Leiden Assay; Protein C with Protein C Reagent; Antithrombin (AT) with INNOVANCE Antithrombin; Protein C with Berichrom Protein C; D-dimer with INNOVANCE D-Dimer",
        "testPrinciple": "The Factor V Leiden Assay is based on the activation of endogenous Protein C. A point mutation in the Factor V gene (Factor V (Leiden) slows the inactivation of factor Va by activated Protein C (APC) causing a hypercoagulable state.",
        "analyticalSpecificity": "No significant interference was observed up to the following interferent concentrations.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The Sysmex Automated Blood Coagulation Analyzer CS-5100 is an automated blood coagulation instrument which analyzes venous plasma samples collected in 3.2% sodium citrate using clotting, chromogenic and immunoassay methods.",
        "regulatoryInformation": "Class II: Factor V Leiden Assay; Coagulation Factor VIII Deficient Plasma; Coagulation Factor IX Deficient Plasma; Class I: LA 1 Screening Reagent, LA 2 Confirmation Reagent, and LA Ratio"
    },
    "K152614.txt": {
        "deviceName": "Xpert Carba-R Assay",
        "intendedUse": "The Xpert Carba-R Assay, performed on the GeneXpert Instrument Systems, is a qualitative in vitro diagnostic test for the detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP gene sequences associated with carbapenem-non-susceptible pure colonies of Enterobacteriaceae, Acinetobacter baumannii, or Pseudomonas aeruginosa grown on blood agar or MacConkey agar.",
        "predicateDevice": "Xpert vanA Assay",
        "indicationsForUse": "Same as the Intended Use",
        "testPrinciple": "The Xpert Carba-R Assay cartridges contain reagents for the detection of blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP gene sequences from isolates of pure cultures of carbapenem-non-susceptible Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.",
        "analyticalSpecificity": "The Xpert Carba-R Assay was examined for analytical specificity by testing a panel of 62 well-characterized carbapenem-susceptible bacteria or bacteria with carbapenem non-susceptibility due to genes or mechanisms other than the Xpert Carba-R target genes.",
        "submissionType": "510(k) Number: K152614",
        "specialConditionsForUse": "For prescription use only. Organisms should be identified and carbapenem non-susceptibility status should be determined prior to testing with the Xpert Carba-R Assay.",
        "deviceDescription": "The Xpert Carba-R Assay is an automated real-time polymerase chain reaction (PCR) in vitro diagnostic test for qualitative detection of the blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP gene sequences from pure colonies of carbapenem non-susceptible Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.",
        "regulatoryInformation": "21 CFR 866.1640 (Antimicrobial susceptibility test powder), Classification: Class II"
    },
    "K143736.txt": {
        "deviceName": "ImmuLisa Enhanced RF IgA Antibody ELISA, ImmuLisa Enhanced RF IgG Antibody ELISA, ImmuLisa Enhanced RF IgM Antibody ELISA, ImmuLisa Enhanced RF IgA/IgG/IgM ELISA",
        "intendedUse": "For the qualitative or semi-quantitative detection of Rheumatoid Factor IgA, IgG, or IgM antibodies in human serum to aid in the diagnosis of rheumatoid arthritis (RA) in conjunction with other laboratory tests and clinical findings.",
        "predicateDevice": "Inova QuantaLite RF IgA ELISA, Inova QuantaLite RF IgG ELISA, Inova QuantaLite RF IgM ELISA",
        "indicationsForUse": "Same as intended use",
        "testPrinciple": "Enzyme-Linked Immunoassay (ELISA)",
        "analyticalSpecificity": "The ImmuLisa Enhanced RF IgA and RF IgG Antibody ELISAs are traceable to in-house standards. The ImmuLisa Enhanced RF IgM Antibody ELISA is traceable directly to the International Rheumatoid Arthritis Standard, NIBSC 64/2.",
        "submissionType": "510(k) Substantial Equivalence Determination",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "Each kit consists of one 12 x8 microplate with individual breakaway microwells coated with purified rabbit IgG antigen, a five-level calibrator set for semi-quantitative analysis, a cut-off calibrator for qualitative analysis, a negative control, a positive control, Tetramethylbenzidine (TMB) chromogenic substrate, stop solution, wash buffer, and diluent.",
        "regulatoryInformation": "21 CFR \u00a7866.5775: Rheumatoid factor immunological test system, Class II, Product code: DHR: System, Test, Rheumatoid Factor"
    },
    "K162705.txt": {
        "deviceName": "VALIDATE D-Dimer Calibration Verification/Linearity Test Kit",
        "intendedUse": "For in vitro diagnostic use in the quantitative determination of linearity, calibration verification and verification of reportable range for the following analyte: D-Dimer in a clinical laboratory setting by laboratory personnel.",
        "predicateDevice": "VALIDATE D-Dimer Calibration Verification/Linearity Test Kit",
        "indicationsForUse": "Same as Intended use",
        "testPrinciple": "The VALIDATE D-Dimer Calibration Verification/Linearity Test Kit is an analyte set of D-Dimer in human plasma base matrix which contains five liquid levels.",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The VALIDATE D-Dimer Calibration Verification/Linearity Test Kit consists of assayed quality control materials used to verify the relationship between the theoretical and actual quantitative performance of D-Dimer.",
        "regulatoryInformation": "21 CFR 864.5425, Multipurpose system for in vitro coagulation studies"
    },
    "K192815.txt": {
        "deviceName": "Elecsys BRAHMS PCT",
        "intendedUse": "Immunoassay for the in vitro quantitative determination of PCT (procalcitonin) in human serum and plasma",
        "predicateDevice": "Elecsys BRAHMS PCT",
        "indicationsForUse": "to aid in the risk assessment of critically ill patients on their first day of ICU admission for progression to severe sepsis and septic shock, to determine the change in PCT level over time as an aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock, to aid in decision making on antibiotic therapy, for inpatients or patients in the emergency department with suspected or confirmed lower respiratory tract infections (LRTI), to aid in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis",
        "testPrinciple": "Electrochemiluminescence immunoassay",
        "analyticalSpecificity": "The specificity of the Elecsys BRAHMS PCT was determined using native human serum samples spiked with potential cross-reactant compounds",
        "submissionType": "Traditional 510(k) Premarket Notification",
        "specialConditionsForUse": "Rx - For Prescription Use Only, The Elecsys BRAHMS PCT is not indicated to be used as a stand-alone diagnostic assay and should be used in conjunction with clinical signs and symptoms of infection and other diagnostic evidence",
        "deviceDescription": "The Elecsys BRAHMS PCT assay is intended for use with the cobas e immunoassay analyzers, PCT Cal1 and Cal2 reagents, and the PreciControl PCT1 and PCT2 as part of the Elecsys BRAHMS PCT Kit",
        "regulatoryInformation": "Class II, 21 CFR 866.3215 - Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis"
    },
    "K183324.txt": {
        "deviceName": "Sensititre 20 - 24 hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint Susceptibility System with Omadacycline",
        "intendedUse": "The Sensititre Haemophilus influenzae/Streptococcus pneumoniae plates are in vitro diagnostic products for clinical susceptibility testing of Haemophilus influenzae, Streptococcus pneumoniae, and Streptococcus species.",
        "predicateDevice": "Sensititre Haemophilus/Streptococcus pneumoniae (HP) MIC Plates",
        "indicationsForUse": "The Sensititre 20 - 24 hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint Susceptibility System is an in vitro diagnostic product for clinical susceptibility testing of fastidious isolates.",
        "testPrinciple": "The Sensititre 20 - 24 hour Haemophilus influenzae/Streptococcus pneumoniae system includes multi-well plastic microtiter plates that contain doubled dilution of antibacterial agents.",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only. The testing of omadacycline with Streptococcus spp. was performed using the AutoReader (OptiRead) and VIZION reading methods and Haemophilus influenzae was only read by VIZION manual method.",
        "deviceDescription": "Sensititre MIC Susceptibility MIC panels are multi-well microtiter plates, dosed with dried, stabilized antimicrobials.",
        "regulatoryInformation": "Class II, Product code: JWY \u2013 Manual Antimicrobial Susceptibility Test System, LRG \u2013 Instrument for Auto Reader and Instrumentation of Overnight Susceptibility Systems, LTT \u2013 Panels, Test, Susceptibility, Antimicrobial"
    },
    "K172745.txt": {
        "deviceName": "ImmuGlo HEp-2 Elite IFA",
        "intendedUse": "The ImmuGlo HEp-2 Elite IFA is an indirect immunofluorescence antibody test for the qualitative or semi-quantitative detection of anti-nuclear antibodies (ANA) of the IgG isotype in human serum utilizing standard HEp-2 cells and engineered HEp-2 cells as a substrate.",
        "predicateDevice": "ImmuGlo ANTINUCLEAR ANTIBODY (ANA) TEST (HEP-2) CELLS",
        "indicationsForUse": "The ImmuGlo HEp-2 Elite IFA is intended for use as an aid in the diagnosis of systemic rheumatic diseases in conjunction with other clinical and laboratory findings.",
        "testPrinciple": "In the indirect IFA method used in this kit, patient sera are incubated on HEp-2 cell substrates to allow binding of antibodies.",
        "analyticalSpecificity": "The ImmuGlo HEp-2 Elite IFA has been tested for cross-reactivity with potentially cross-reactive disease sera and interference with potentially interfering substances.",
        "submissionType": "510(k) Substantial Equivalence Determination",
        "specialConditionsForUse": "For Prescription Use Only",
        "deviceDescription": "The kit is an indirect immunofluorescence assay (IFA) to detect IgG anti-nuclear antibodies (ANA) against proteins presented in HEp-2 cell lines.",
        "regulatoryInformation": "21 CFR \u00a7866.5100 \u2012 Antinuclear antibody immunological test system, Class II, Product code: DHN \u2012 Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control"
    },
    "K161510.txt": {
        "deviceName": "VITEK 2 AST-GN Ceftolozane/Tazobactam",
        "intendedUse": "The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp. and clinically significant yeast.",
        "predicateDevice": "VITEK 2 AST-GN Doxycycline",
        "indicationsForUse": "VITEK 2 Gram Negative Ceftolozane/Tazobactam is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents.",
        "testPrinciple": "The VITEK 2 and VITEK 2 Compact Systems utilize automated growth-based detection using attenuation of light measured by an optical scanner.",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "Prescription use only. The ability of the AST card to detect resistance with the following combination(s) is unknown because an insufficient number of resistant strains were available at the time of comparative testing.",
        "deviceDescription": "The VITEK 2 AST card is a miniaturized, abbreviated and automated version of the doubling dilution technique for determining the minimum inhibitory concentration (MIC).",
        "regulatoryInformation": "Class II, 21 CFR 866.1645 Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System"
    },
    "K181915.txt": {
        "deviceName": "PixoTest POCT System",
        "intendedUse": "The PixoTest POCT System, consisting of PixoTest POCT Analyzer and PixoTest A1c Test Kit, is used for the quantitative measurement of glycated hemoglobin (%HbA1c) in venous whole blood samples.",
        "predicateDevice": "SD A1cCare System",
        "indicationsForUse": "The PixoTest POCT System is intended to monitor long term glycemic control in individuals previously diagnosed with diabetes mellitus.",
        "testPrinciple": "The PixoTest A1c Test kit uses an anti-HbA1c antibody which is specific for the first few amino acid residues of the glycated N-terminus of the \u00df-chain of hemoglobin A0.",
        "analyticalSpecificity": "Endogenous and exogenous substances were spiked at two levels into each of two K2-EDTA venous whole blood samples. The following substances demonstrated no significant interference at the concentrations described below: Albumin, Unconjugated bilirubin, Glycated Albumin, Lipemia/Intralipid, Rheumatoid Factor, Total protein, Urea, Aspirin (acetylsalicylic acid), Ascorbic acid, Acetaminophen, Acetylcysteine, Ampicillin, Caffeine, Cefoxitin, Cyclosporine A, Doxycycline, Glyburide, Hydroxyzine dihydrochloride, Heparin, Ibuprofen, Levodopa (L-dopa), Dopamine, Methyldopa, Metformin, Metronidazole, Rifampicin, Glibenclamide",
        "submissionType": "New device",
        "specialConditionsForUse": "For prescription use only. This test should not be used in monitoring daily glucose control and should not be used to replace daily home testing of urine and blood glucose levels. This test should not be used for analyzing samples from patients with conditions causing shortened red blood cell survival, such as hemolytic diseases, pregnancy and significant acute or chronic blood loss.",
        "deviceDescription": "The iXensor PixoTest POCT System consists of the following components: PixoTest POCT Analyzer, including PixoHealth POCT A1c App, USB Charger, USB Type C Charge Cable, PixoTest POCT Calibration Card, Instructions for Use, PixoTest POCT A1c Test Kit, including PixoTest A1c Test Strips, Spoits, Buffer Solution Tubes, Instructions for Use",
        "regulatoryInformation": "Classification Name: Assay, Glycosylated Hemoglobin, Regulation: 21 CFR 864.7470, Device Class: II, Product Code: LCP, Panel: Hematology (81), Device: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use, 21CFR: 862.2160, Device Class: I, Product Code: JJE, Panel: Chemistry (75)"
    },
    "K182389.txt": {
        "deviceName": "Sysmex XN-L Automated Hematology Analyzer",
        "intendedUse": "The Sysmex XN-L analyzer is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening patient populations found in clinical laboratories.",
        "predicateDevice": "Sysmex XN-Series (XN-10, XN-20) Automated Hematology Analyzer",
        "indicationsForUse": "The XN-L analyzer classifies and enumerates the following parameters in venous and capillary whole blood: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT, NEUT%/#, LYMPH%/#, MONO%/#, EO%/#, BASO%/#, IG%/#, RDW-CV, RDW-SD, MPV, RET%/#, IRF, RET-He and has a Body Fluid mode for body fluids.",
        "testPrinciple": "Hydro Dynamic Focusing (DC Detection), flow cytometry method using a semiconductor laser and SLS hemoglobin method.",
        "analyticalSpecificity": "Not Available",
        "submissionType": "Expand Intended Use to include pediatric subjects under the age of 2 years old.",
        "specialConditionsForUse": "For prescription use only.",
        "deviceDescription": "The XN-L analyzer is a quantitative multi-parameter automated differential cell counter that classifies and enumerates whole blood and body fluid parameters by means of electrical impedance, laser light scattering, and fluorescent labeling.",
        "regulatoryInformation": "21 CFR 864.5220, Automated differential cell counter, Class II, Product code: GKZ, Counter, Differential Cell, Panel: Hematology (81)"
    },
    "K183415.txt": {
        "deviceName": "VITEK 2 AST-Gram Negative Imipenem",
        "intendedUse": "The VITEK 2 Gram-negative Susceptibility Card is intended for use with the VITEK 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant aerobic Gram-negative bacilli to antimicrobial agents when used as instructed.",
        "predicateDevice": "VITEK 2 AST-GN Amikacin",
        "indicationsForUse": "VITEK 2 AST-Gram Negative Imipenem is designed for antimicrobial susceptibility testing of Gram negative bacilli and is intended for use with the VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents.",
        "testPrinciple": "The VITEK 2 and VITEK 2 Compact Systems utilize automated growth-based detection using attenuation of light measured by an optical scanner.",
        "analyticalSpecificity": "N/A",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "Prescription use only. Perform an alternative method of testing prior to reporting of results for the following antibiotic/organism combinations: Imipenem (ipm05n): Klebsiella (Enterobacter) aerogenes, Proteus species, Providencia species, Morganella species and Serratia species.",
        "deviceDescription": "The VITEK 2 AST card is a miniaturized, abbreviated and automated version of the doubling dilution technique for determining the minimum inhibitory concentration (MIC).",
        "regulatoryInformation": "Class II, 21 CFR 866.1645 Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System"
    },
    "K173927.txt": {
        "deviceName": "Elecsys BRAHMS PCT",
        "intendedUse": "Immunoassay for the in vitro quantitative determination of PCT (procalcitonin) in human serum and plasma (K2 \u2013EDTA, K3-EDTA and Li-Heparin)",
        "predicateDevice": "BRAHMS PCT sensitive KRYPTOR",
        "indicationsForUse": "to aid in the risk assessment of critically ill patients on their first day of ICU admission for progression to severe sepsis and septic shock, to determine the change in PCT level over time as an aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission, to aid in decision making on antibiotic therapy, for inpatients or patients in the emergency department with suspected or confirmed lower respiratory tract infections (LRTI) \u2013 defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD), to aid in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis",
        "testPrinciple": "The Elecsys BRAHMS PCT assay is a two-step sandwich immunoassay with streptavidin microparticles and an electrochemiluminescence detection system",
        "analyticalSpecificity": "The Elecsys BRAHMS PCT assay on Elecsys and cobas e analyzers does not show any significant cross-reaction with the following substances",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only. The Elecsys BRAHMS PCT assay should not be used as a sole basis for diagnosis for determining the risk of 28 day all-cause mortality",
        "deviceDescription": "The reagent working solutions include: Rackpack (kit placed on analyzer) \u00b7 M: Streptavidin-coated microparticles \u00b7 R1: Anti-PCT-Ab~biotin \u00b7 R2: Anti-PCT \u2013 Ab~Ru (bpy)",
        "regulatoryInformation": "Class II (Special Controls), 21 CFR 866.3215; Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis"
    },
    "K172109.txt": {
        "deviceName": "Liofilchem MIC Test Strip (MTS)",
        "intendedUse": "The Liofilchem MIC Test Strip (MTS) is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria",
        "predicateDevice": "Liofilchem MTS, vancomycin",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "MTS are made of specialized paper impregnated with a predefined concentration gradient of antibiotic, across 15 two-fold dilutions like those of a conventional MIC method",
        "analyticalSpecificity": "Not Applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use",
        "deviceDescription": "The Erythromycin MIC Test Strip (MTS) consists of specialized paper impregnated with a predefined concentration gradient of Erythromycin across 15 two-fold dilutions like those of a conventional MIC method",
        "regulatoryInformation": "Regulation section: 866.1640 Antimicrobial Susceptibility Test Powder, Classification: II, Product code: JWY - Manual Antimicrobial Test Systems"
    },
    "K150617.txt": {
        "deviceName": "cobas HSV 1 and 2 Test",
        "intendedUse": "The cobas HSV 1 and 2 Test is an automated, qualitative in vitro diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection and differentiation of Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) DNA in clinician-collected anogenital lesion specimens from symptomatic male and female patients.",
        "predicateDevice": "BD ProbeTec Herpes Simplex Viruses (HSV 1 & 2) Qx Amplified DNA Assays",
        "indicationsForUse": "The cobas HSV 1 and 2 Test is intended for use as an aid in diagnosis of anogenital HSV-1 and HSV-2 infections in symptomatic patients.",
        "testPrinciple": "The cobas HSV 1 and 2 Test utilizes real-time PCR technology to detect the conserved regions of HSV-1 Thymidine Kinase and HSV-1 DNA Polymerase as well as HSV-2 Thymidine Kinase and HSV-2 Glycoprotein B genes.",
        "analyticalSpecificity": "The analytical specificity/cross reactivity of the cobas HSV 1 and 2 Test was assessed by testing a panel of organisms that could be present in anogenital swab specimens.",
        "submissionType": "510(k) Clearance of New Device",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The cobas HSV 1 and 2 Test on the cobas 4800 system is a real-time polymerase chain reaction (PCR) for the direct detection and differentiation of HSV-1 and HSV-2 DNA in clinician-collected anogenital lesion specimens, collected in MSwab Collection, Transport and Preservation System from symptomatic patients.",
        "regulatoryInformation": "The cobas HSV 1 and 2 Test is classified as a Class II device under 21 CFR 866.3305"
    },
    "K151767.txt": {
        "deviceName": "Trinidad CH system",
        "intendedUse": "The Trinidad CH System is an automated, clinical chemistry analyzer designed to perform in vitro diagnostic tests on clinical specimens.",
        "predicateDevice": "Siemens ADVIA 1800 Chemistry System",
        "indicationsForUse": "The TD-LYTE Integrated Multisensor (Na, K, Cl) is intended for in vitro diagnostic use in the quantitative determination of sodium, potassium, and chloride (Na, K, Cl) in human serum, plasma, and urine using the Trinidad CH system.",
        "testPrinciple": "The TD-LYTE Integrated Multisensor (Na, K, Cl) uses indirect Integrated Multisensor Technology (IMT).",
        "analyticalSpecificity": "Interference studies were performed according to CLSI EP-7A guidance to determine the effects from potential interferents on the ISE and albumin assays.",
        "submissionType": "New devices",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The Siemens Healthcare Diagnostics Trinidad CH system is a floor model, fully automated, microprocessor-controlled, integrated instrument system that uses prepackaged reagent packs to measure a variety of analytes in human body fluids.",
        "regulatoryInformation": "Product Code: JGS, Classification: Class II, Regulation Section: 21 CFR 862.1665 Sodium Test System"
    },
    "K150144.txt": {
        "deviceName": "VisuCon-F Low Fibrinogen Control Plasma",
        "intendedUse": "The VisuCon-F Low Fibrinogen Control Plasma is an assayed control plasma prepared from de-fibrinated human plasma intended for use in the quality control of quantitative fibrinogen assays in the low abnormal range.",
        "predicateDevice": "Cryocheck Low Fibrinogen Control",
        "indicationsForUse": "Same as intended use",
        "testPrinciple": "The VisuCon-F Low Fibrinogen control is to be utilized to monitor the performance of fibrinogen assays in the low abnormal range using the Clauss clotting method in mechanical instruments.",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The VisuCon-F Low Fibrinogen Control Plasma is a pool of de-fibrinated citrated human plasma collected from a minimum of 10 donors, buffered with 0.02 M HEPES buffer.",
        "regulatoryInformation": "21 CFR \u00a7864.5425, Multipurpose system for in vitro coagulation studies"
    },
    "K153137.txt": {
        "deviceName": "HemosIL HIT-Ab(PF4-H)",
        "intendedUse": "The HemosIL HIT-Ab(PF4-H) is a qualitative, fully automated, latex enhanced immunoassay for the detection of anti-platelet factor 4/heparin (PF4/H) antibodies.",
        "predicateDevice": "Asserachrom HPIA Test kit",
        "indicationsForUse": "For use in adult population suspected of HIT. Not for use in isolation to exclude HIT.",
        "testPrinciple": "The HemosIL HIT-Ab(PF4-H) kit is a latex particle enhanced immuno-turbidimetric assay to detect total Anti\u2010PF4/Heparin (PF4/H) antibodies found in HIT patients.",
        "analyticalSpecificity": "Analytical specificity for detecting anti-HIT antibodies was tested using 10 \u03bcL of PF4/ Heparin complex to inhibit reactivity of the assay in 18 citrated patient plasma samples.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use",
        "deviceDescription": "The HemosIL HIT-Ab(PF4-H) kit consists of: Latex Reagent, Stabilizer, Complex, Calibrator, and Controls.",
        "regulatoryInformation": "Class II, 21 CFR 864.7695, Platelet factor 4 radioimmunoassay, 21 CFR 864.5425, Multipurpose system for in vitro coagulation studies"
    },
    "K170127.txt": {
        "deviceName": "HardyDisk Ceftolozane/Tazobactam, (30/10\u00b5g) - C/T40",
        "intendedUse": "in vitro agar diffusion susceptibility testing",
        "predicateDevice": "HardyDisk Tigecycline 15\u00b5g",
        "indicationsForUse": "to determine the susceptibility of bacteria to Ceftolozane/Tazobactam",
        "testPrinciple": "agar diffusion (Kirby-Bauer) methodology",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "6-mm diameter white filter paper disks impregnated with a known concentration of 30\u00b5g Ceftolozane and 10\u00b5g of Tazobactam",
        "regulatoryInformation": "21 CFR 866.1620 Antimicrobial Susceptibility Test Disc, Class II, Product code: JTN \u2013 Susceptibility Test Disc, Antimicrobial"
    },
    "K143548.txt": {
        "deviceName": "TRUE METRIX GO Blood Glucose Meter",
        "intendedUse": "The TRUE METRIX GO Self Monitoring Blood Glucose System is intended for the quantitative measurement of glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip.",
        "predicateDevice": "Bayer Ascensia Contour Blood Glucose Monitoring System",
        "indicationsForUse": "The TRUE METRIX GO Self Monitoring Blood Glucose System is intended to be used by a single person and not shared. The TRUE METRIX GO Self Monitoring Blood Glucose System is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control.",
        "testPrinciple": "The TRUE METRIX GO Self Monitoring Blood Glucose System uses electrochemical methodologies. The system quantitatively measures blood glucose levels using an amperometric method. The system employs flavin adenine dinucleotide-glucose dehydrogenase (GDH-FAD) enzyme chemistry.",
        "analyticalSpecificity": "The sponsor used venous whole blood samples adjusted to two glucose concentrations, 80 mg/dL and 300 mg/dL. Each of these samples was divided into a test pool and a control pool and each of the potential endogenous and exogenous interfering substances was added to the test pool.",
        "submissionType": "New device",
        "specialConditionsForUse": "For In-Vitro Diagnostic Use Only. For over-the-counter use. Not for screening or diagnosis of diabetes mellitus. Not for use on critically ill patients, patients in shock, dehydrated patients or hyper-osmolar patients. Inaccurate results may occur in severely hypotensive individuals or in dehydrated patients or patients in shock.",
        "deviceDescription": "The TRUE METRIX GO Self Monitoring Blood Glucose System contains a blood glucose meter and TRUE METRIXTM Blood Glucose Test Strips. These are no code meters. The meter is designed to affix (twist) onto the cap of a TRUE METRIX strip vial.",
        "regulatoryInformation": "21 CFR 862.1345, Glucose test system. Classification: Class II. Product code: NBW, System, Test, Blood Glucose, Over the Counter. LFR, Glucose Dehydrogenase, Glucose"
    },
    "K163517.txt": {
        "deviceName": "Liofilchem MIC Test Strip (MTS)",
        "intendedUse": "The Liofilchem MIC Test Strip (MTS) is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of non-fastidious Gram negative and Gram positive aerobic bacteria",
        "predicateDevice": "Liofilchem MIC Test Strip (MTS) \u2013 Vancomycin 0.016 \u2013 256 \u03bcg/mL",
        "indicationsForUse": "Staphylococcus aureus (including methicillin-resistant isolates) and Enterococcus faecalis (vancomycin-susceptible isolates only)",
        "testPrinciple": "MTS are made of specialized paper impregnated with a predefined concentration gradient of antibiotic, across 15 two-fold dilutions like those of a conventional MIC method",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) Premarket Notification",
        "specialConditionsForUse": "Prescription use only",
        "deviceDescription": "The Telavancin MIC Test Strip (MTS) is made of special high quality paper impregnated with a predefined concentration of gradient Telavancin, across 15 two-fold dilutions",
        "regulatoryInformation": "Regulation section: 866.1640 Antimicrobial Susceptibility Test Powder, Classification: II, Product code: JWY \u2013 Manual Antimicrobial Test Systems"
    },
    "K152495.txt": {
        "deviceName": "Wondfo Propoxyphene Urine Test",
        "intendedUse": "The Wondfo Propoxyphene Urine Test is an immunochromatographic assay for the qualitative determination of d-Propoxyphene in human urine at a cutoff concentration of 300 ng/mL.",
        "predicateDevice": "Wondfo Propoxyphene Urine Test",
        "indicationsForUse": "The test is available in a dip card format and a test cup format. It is intended for prescription use and over the counter use.",
        "testPrinciple": "The assay type is a competitive immunoassay constructed on a lateral flow device.",
        "analyticalSpecificity": "See k121557",
        "submissionType": "Addition of an over-the-counter (OTC) claim",
        "specialConditionsForUse": "For over-the-counter and prescription use.",
        "deviceDescription": "The Wondfo Propoxyphene Urine Test is a rapid test for the qualitative detection of Propoxyphene in urine samples.",
        "regulatoryInformation": "21 CFR \u00a7862.3700, Class II, Product code: JXN"
    },
    "K181324.txt": {
        "deviceName": "FilmArray Pneumonia Panel plus",
        "intendedUse": "The FilmArray Pneumonia Panel plus is a multiplexed nucleic acid test intended for use with FilmArray, FilmArray 2.0, or FilmArray Torch systems for the simultaneous detection and identification of nucleic acids from Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and multiple respiratory viral and bacterial nucleic acids, as well as select antimicrobial resistance genes, in sputum-like specimens (induced or expectorated sputum, or endotracheal aspirates) or bronchoalveolar lavage (BAL)-like specimens (BAL or mini-BAL) obtained from individuals meeting MERS-CoV clinical and/or epidemiological criteria.",
        "predicateDevice": "FilmArray Respiratory Panel 2 plus (RP2plus)",
        "indicationsForUse": "The FilmArray Pneumonia Panel plus is intended for use with FilmArray, FilmArray 2.0, or FilmArray Torch systems for the simultaneous detection and identification of nucleic acids from Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and multiple respiratory viral and bacterial nucleic acids, as well as select antimicrobial resistance genes, in sputum-like specimens (induced or expectorated sputum, or endotracheal aspirates) or bronchoalveolar lavage (BAL)-like specimens (BAL or mini-BAL) obtained from individuals meeting MERS-CoV clinical and/or epidemiological criteria.",
        "testPrinciple": "The FilmArray Pneumonia Panel plus pouch is a closed system disposable that stores all the necessary reagents for sample preparation, reverse transcription, polymerase chain reaction (PCR), and detection in order to isolate, amplify, and detect nucleic acid from multiple lower respiratory pathogens within a single bronchoalveolar lavage (BAL)-like (BAL or mini-BAL) or sputum-like (sputum or ETA) specimen.",
        "analyticalSpecificity": "The FilmArray Pneumonia Panel plus has been designed to detect and identify multiple respiratory viral and bacterial nucleic acids, as well as select antimicrobial resistance genes.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only. For in vitro diagnostic use only.",
        "deviceDescription": "The FilmArray Pneumonia Panel plus is a multiplexed nucleic acid test intended for use with FilmArray, FilmArray 2.0, or FilmArray Torch systems for the simultaneous detection and identification of nucleic acids from Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and multiple respiratory viral and bacterial nucleic acids, as well as select antimicrobial resistance genes, in sputum-like specimens (induced or expectorated sputum, or endotracheal aspirates) or bronchoalveolar lavage (BAL)-like specimens (BAL or mini-BAL) obtained from individuals meeting MERS-CoV clinical and/or epidemiological criteria.",
        "regulatoryInformation": "The FilmArray Pneumonia Panel plus is classified as a Class II device with Special Controls."
    },
    "K162840.txt": {
        "deviceName": "Elecsys Vitamin D total II",
        "intendedUse": "The Elecsys Vitamin D total II assay is intended for the quantitative determination of total 25-hydroxyvitamin D in human serum and plasma. This assay is to be used as an aid in the assessment of vitamin D sufficiency in adults.",
        "predicateDevice": "Elecsys Vitamin D Assay",
        "indicationsForUse": "The Elecsys Vitamin D total II assay is intended for the quantitative determination of total 25-hydroxyvitamin D in human serum and plasma. This assay is to be used as an aid in the assessment of vitamin D sufficiency in adults.",
        "testPrinciple": "The Elecsys Vitamin D total II assay employs a competitive protein binding assay which uses Vitamin D Binding Protein for detection of 25-OH Vitamin D.",
        "analyticalSpecificity": "The assay has been evaluated for potential interference from endogenous substances and exogenous substances, including bilirubin, hemoglobin, intralipid, triglyceride, cholesterol, biotin, total protein, rheumatoid factor, and immunoglobulin.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only. Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.",
        "deviceDescription": "The Elecsys Vitamin D total II reagent working solutions include: PT1 Pretreatment reagent 1, PT2 Pretreatment reagent 2, M Streptavidin-coated microparticles, R1 Vitamin D binding protein\u2011Ru/(bpy), and R2 25\u2011hydroxyvitamin D~biotin.",
        "regulatoryInformation": "Class II, 21 CFR 862.1825, Vitamin D Test System, 21 CFR 862.1150, Calibrator, 21 CFR 862.1660, Quality Control Material (assayed and unassayed)"
    },
    "K173887.txt": {
        "deviceName": "cobas CT/NG",
        "intendedUse": "The cobas CT/NG on the cobas 6800/8800 system is an automated, qualitative in vitro nucleic acid diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) DNA in male and female urine, clinician-instructed self-collected vaginal swab specimens (collected in a clinical setting), clinician-collected vaginal swab specimens, and endocervical swab specimens, all collected in cobas PCR Media (Roche Molecular Systems, Inc.), and cervical specimens collected in PreservCyt solution.",
        "predicateDevice": "cobas CT/NG v2.0 Test",
        "indicationsForUse": "The cobas CT/NG assay is intended for use as an aid in the diagnosis of chlamydial and gonococcal disease in both symptomatic and asymptomatic individuals.",
        "testPrinciple": "The cobas CT/NG assay is based on fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection.",
        "analyticalSpecificity": "The cobas CT/NG assay detects Chlamydia trachomatis and Neisseria gonorrhoeae DNA from urogenital specimens.",
        "submissionType": "510(k) submission",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The cobas CT/NG assay is a new fully automated, qualitative real-time PCR assay performed on the cobas 6800 System and cobas 8800 System.",
        "regulatoryInformation": "The device is classified as Class II and is regulated under 21 CFR 866.3390 - Neisseria spp. direct serological test reagents."
    },
    "K162895.txt": {
        "deviceName": "Elecsys Troponin T Gen 5 STAT Immunoassay",
        "intendedUse": "For the in vitro quantitative determination of cardiac troponin T (cTnT) in lithium heparin plasma. The immunoassay is intended to aid in the diagnosis of myocardial infarction.",
        "predicateDevice": "Elecsys Troponin T STAT Assay, Elecsys Troponin T CalSet, Elecsys PreciControl Troponin, Elecsys CA 15-3 CalCheck 5",
        "indicationsForUse": "Aid in the diagnosis of myocardial infarction",
        "testPrinciple": "The test uses both ruthenium-labeled and biotin-labeled antibodies to form a sandwich complex with cardiac troponin T (cTnT).",
        "analyticalSpecificity": "The potentially interfering compounds did not interfere with the performance of the device (i.e., did not result in bias >10%).",
        "submissionType": "New device",
        "specialConditionsForUse": "For prescription use, For in vitro diagnostic use, The positive predictive value for females using the lower sex-specific cut-off (14 ng/L) is lower when compared to the higher cut-off of 19 ng/L.",
        "deviceDescription": "The reagents are: Streptavidin-coated microparticles, Anti-troponin T-Ab~biotin, Anti-troponin T-Ab~Ru(bpy)",
        "regulatoryInformation": "Class II, 21 CFR 862.1215 - Creatine phosphokinase/creatine kinase or isoenzymes test system"
    },
    "K180264.txt": {
        "deviceName": "Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test Kit",
        "intendedUse": "The Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test Kit is intended as a qualitative presumptive (first-step) test for the detection of IgG and IgM antibodies to B. burgdorferi sensu stricto in human serum from symptomatic patients or people suspected of infection.",
        "predicateDevice": "Trinity Biotech Captia Borrelia burgdorferi IgG/IgM ELISA Test Kit",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "Enzyme Immunoassay",
        "analyticalSpecificity": "97.3% in endemic region and 98.0% in non-endemic region",
        "submissionType": "510(k) Premarket Notification",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM test consists of antigenic proteins specific for B. burgdorferi (sensu stricto) which are either purified or cloned and expressed in the surrogate host E.coli.",
        "regulatoryInformation": "Class II, Product code: LSR; Reagent, Borrelia Serological Reagent, Regulation section: 21 CFR 866.3830"
    },
    "K160682.txt": {
        "deviceName": "CONTOUR NEXT ONE Blood Glucose Meter",
        "intendedUse": "The Contour Next ONE blood glucose monitoring system is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertips or palm as an aid in monitoring the effectiveness of a diabetes control program",
        "predicateDevice": "CONTOUR NEXT USB Blood Glucose Meter",
        "indicationsForUse": "The Contour Next ONE blood glucose monitoring system is intended to be used by a single person and should not be shared. The Contour Next ONE blood glucose monitoring system is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid in monitoring the effectiveness of a diabetes control program",
        "testPrinciple": "The active ingredients on the Contour NEXT Test Strips are the enzyme, FAD dependent glucose dehydrogenase (FAD-GDH), and an electron mediator. When a blood sample fills the reaction zone of the test strip, a chemical reaction occurs in which the FAD-GDH enzyme causes electrons to pass from glucose molecules to co-factor and the mediator in the test strip",
        "analyticalSpecificity": "Analytical specificity was assessed for twenty three endogenous and exogenous substances with two venous blood samples with two levels of glucose",
        "submissionType": "New device",
        "specialConditionsForUse": "For in vitro diagnostic use only. Do not use for diagnosis of, or screening of diabetes. Alternative site testing should be done only when glucose is not changing rapidly. The Contour Next ONE meter is not indicated for neonatal use. The system should not be used to test critically ill patients. The system should not be used by persons with reduced peripheral blood flow",
        "deviceDescription": "The Contour NEXT One Blood Glucose Monitoring System consists of the Contour Next One blood glucose meter, the Contour Next test strips, two levels of the Contour Next control solutions, lancing device, lancets, clear endcap, and user manual",
        "regulatoryInformation": "Class II, 21 CFR 862.1345, Product code: NBW, Blood glucose test system, over the counter, LFR, Glucose Dehydrogenase, Glucose"
    },
    "K181092.txt": {
        "deviceName": "CHROMID CARBA agar",
        "intendedUse": "The CHROMID CARBA agar is a selective and differential chromogenic medium that is intended for the qualitative detection and presumptive identification of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in rectal swab specimens from patients at risk of colonization.",
        "predicateDevice": "bioM\u00e9rieux CHROMID VRE agar",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "CHROMID CARBA agar consists of nutritive medium containing peptones and a mixture of antimicrobial agents that select for growth of carbapenemase-producing Enterobacteriaceae (CPE), and chromogenic substrates that enable presumptive identification of the most common carbapenemase-producing species.",
        "analyticalSpecificity": "The results of the Analytical Specificity Study demonstrate that E. coli and K. pneumoniae with carbapenemases other than KPC-type carbapenemase may exhibit pink-burgundy or blue-green/blue-grey colonies on CHROMID CARBA agar, although performance with such isolates has not been established.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only. A lack of growth or the absence of pink-burgundy or blue-green/blue-grey colonies does not preclude the carriage of carbapenemase producing organisms.",
        "deviceDescription": "CHROMID CARBA agar is a selective and differential culture medium that contains a combination of antimicrobial agents and chromogenic substrates.",
        "regulatoryInformation": "21 CFR 866.1700: Culture medium for antimicrobial susceptibility tests, Class II, Product code: JSO"
    },
    "K170464.txt": {
        "deviceName": "StatStrip Xpress Blood Glucose Monitoring System",
        "intendedUse": "The StatStrip Xpress Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood obtained from the fingertip.",
        "predicateDevice": "StatStrip Xpress Blood Glucose Monitoring System",
        "indicationsForUse": "It is intended for self-testing outside the body by people with diabetes mellitus as an aid to monitor the effectiveness of diabetes control.",
        "testPrinciple": "The StatStrip Xpress Blood Glucose Monitoring System measures glucose levels using disposable test strips and a handheld meter.",
        "analyticalSpecificity": "Potential interference from some common endogenous and exogenous substances was established in k132121.",
        "submissionType": "This submission seeks changes in labeling for the previously cleared StatStrip Xpress Blood Glucose Monitoring System (k160156).",
        "specialConditionsForUse": "For over-the-counter use, For single-patient use only, Critically ill patients should not be tested with this device.",
        "deviceDescription": "The modified StatStrip Xpress Blood Glucose Monitoring System, which includes StatStrip Xpress Blood Glucose Monitor, StatStrip Xpress Glucose Test Strips, and StatStrip Xpress Glucose Control Solutions.",
        "regulatoryInformation": "21 CFR 862.1345, Glucose test system, Class II, Product code: NBW, System, Test, Blood Glucose, Over The Counter"
    },
    "K150041.txt": {
        "deviceName": "CORA System",
        "intendedUse": "The CORA System is intended for in vitro diagnostic use to provide semi-quantitative indications of the hemostasis state of a blood sample.",
        "predicateDevice": "Thromboelastograph Coagulation Analyzer (TEG)-5000 Series, Haemoscope Corporation",
        "indicationsForUse": "The indication for CORA System use is with adult patients where an evaluation of their blood hemostasis properties is desired.",
        "testPrinciple": "The CORA technology is based on a disposable containing up to four independent measurement cells.",
        "analyticalSpecificity": "The Kaolin with Heparinase assay was tested to validate that 6 IU of Heparinase per 1 mL of blood will effectively neutralize the effects of both Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH) on Kaolin-activated citrated whole blood samples.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "Prescription Use Only",
        "deviceDescription": "The CORA System consists of a four-channel diagnostic analyzer with integrated computer module, system reagents, and Abnormal Quality Control material and microfluidic test cartridges.",
        "regulatoryInformation": "21 CFR 864.5425, Multipurpose system for in vitro coagulation studies, 21 CFR 864.5700, Automated platelet aggregation system"
    },
    "K181043.txt": {
        "deviceName": "StatStrip Glucose Hospital Meter System",
        "intendedUse": "for point-of-care, in vitro diagnostic, multiple-patient use for the quantitative determination of glucose in capillary finger stick, venous whole blood, arterial whole blood, neonate arterial whole blood and neonate heel stick specimens throughout all hospital and all professional healthcare settings",
        "predicateDevice": "Nova StatStrip Glucose Hospital Meter System",
        "indicationsForUse": "for determining dysglycemia",
        "testPrinciple": "electrochemical biosensor technology and the principle of capillary action",
        "analyticalSpecificity": "evaluated in k060345 and k132121 for potential interference from common endogenous and exogenous substances",
        "submissionType": "Dual 510(k) and CLIA Waiver by Application",
        "specialConditionsForUse": "- For prescription use only, - For in vitro diagnostic use only, - The system has not been evaluated for use with neonate venous blood, - Temperature and humidity extremes, - Altitudes above 15,000 feet, - Specimens, - Fluoride, EDTA, Sodium, and Ammonium blood collection devices should not be used, - Use only whole blood, - Should only be used with single-use, auto-disabling lancing devices, - Caution should be exercised when testing capillary whole blood",
        "deviceDescription": "The StatStrip Glucose Hospital Meter System consists of a hand held StatStrip Glucose Hospital meter, StatStrip Test Strips, Nova StatStrip Control Solutions, Nova StatStrip Linearity Test Kit solutions, docking station, Quick Reference Guide, and User Manual",
        "regulatoryInformation": "Product Code: PZI, Regulation Name: Glucose Test System, Classification: II, Regulation Section: 21 CFR 862.1345, Panel: Clinical Chemistry"
    },
    "K161714.txt": {
        "deviceName": "Immunalysis Barbiturates Urine Enzyme Immunoassay",
        "intendedUse": "The Immunalysis Barbiturates Urine Enzyme Immunoassay is a homogeneous enzyme immunoassay with a cutoff of 200 ng/mL. The assay is intended for use in laboratories for the qualitative and semi-quantitative analysis of Barbiturates in human urine with automated clinical chemistry analyzers.",
        "predicateDevice": "DRI Barbiturates EIA Assay",
        "indicationsForUse": "The Immunalysis Barbiturates Urine Enzyme Immunoassay is intended for use in laboratories for the qualitative and semi-quantitative analysis of Barbiturates in human urine with automated clinical chemistry analyzers.",
        "testPrinciple": "This assay uses a recombinant and a mouse monoclonal antibody, both directed against Secobarbital. The assay is based on the competition of Barbiturates labeled enzyme glucose-6-phosphate dehydrogenase (G6PDH) and the free drug in the urine sample for the fixed amount of antibody binding sites.",
        "analyticalSpecificity": "The sponsor performed cross-reactivity studies in both qualitative and semi-quantitative modes by spiking various barbiturates or structurally related compounds into drug free urine at levels that will yield a result that is equivalent to the assay cutoff (200 ng/mL).",
        "submissionType": "New device",
        "specialConditionsForUse": "For prescription use only.",
        "deviceDescription": "The Immunalysis Barbiturates Urine Enzyme Immunoassay Kit reagents are provided as ready to use liquids and consist of the following reagents: The Antibody/ Substrate Reagent and The Enzyme Conjugate Reagent.",
        "regulatoryInformation": "21 CFR 862.3150 Barbiturate test system, 21 CFR 862.3200, Clinical toxicology calibrator, Class II, Product code: DIS, DKB"
    },
    "K142965.txt": {
        "deviceName": "Virtuoso System for IHC PR (1E2) Using the VENTANA iScan HT",
        "intendedUse": "The Virtuoso System provides automated digital slide creation, management, analysis, and viewing. It is intended for in vitro diagnostic use as an aid to the pathologist in the display, detection, counting, review and classification of tissues and cells of clinical interest based on particular morphology, color, intensity, size, pattern and shape.",
        "predicateDevice": "Virtuoso System for IHC PR (1E2), k111869",
        "indicationsForUse": "The Virtuoso System for IHC PR (1E2) using the VENTANA iScan HT is for the digital read application. This particular Virtuoso system is intended for use as an aid to the pathologist in the qualitative detection of progesterone receptor (PR) protein in formalin-fixed, paraffin-embedded normal and neoplastic tissue.",
        "testPrinciple": "Manual scoring of digital images on a computer monitor of progesterone receptor (PR) (1E2) immunohistochemistry (IHC) stained slides using the VENTANA iScan HT scanner.",
        "analyticalSpecificity": "Not explicitly stated in the document",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The Virtuoso System for IHC PR (1E2) Using the VENTANA iScan HT is an instrument-plus-software system designed to assist the qualified pathologist in the assessment of protein expression in IHC stained histologic sections from formalin-fixed, paraffin-embedded (FFPE) breast tissues.",
        "regulatoryInformation": "21 CFR \u00a7864.1860, Immunohistochemistry reagents and kits, Class II, Product code: OEO - Automated Digital Image Manual Interpretation Microscope"
    },
    "K181889.txt": {
        "deviceName": "Liofilchem MTS Penicillin 0.002-32 \u03bcg/mL",
        "intendedUse": "The Liofilchem MTS (MIC Test Strip) Penicillin 0.002-32 \u03bcg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria.",
        "predicateDevice": "Liofilchem MTS, vancomycin",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "The Liofilchem MIC Test Strips (MTS) are made of specialized paper impregnated with a predefined concentration gradient of antibiotic, across 15 two-fold dilutions similar to dilutions used by conventional MIC methods.",
        "analyticalSpecificity": "Not Applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATIONS",
        "specialConditionsForUse": "\u00b7 For prescription use \u00b7 The ability of the MTS to detect resistant isolates with the following drug/bacterial species combinations is unknown because resistant isolates were either not available or an insufficient number was encountered at the time of comparative testing.",
        "deviceDescription": "The Penicillin MIC Test Strip (MTS) consists of specialized paper impregnated with a predefined concentration gradient of Penicillin across 15 two-fold dilutions similar to dilutions used by conventional MIC methods.",
        "regulatoryInformation": "Regulation section: 866.1640 Antimicrobial Susceptibility Test Powder, Classification: II, Product code: JWY - Manual Antimicrobial Susceptibility Test Systems, Panel: 83 \u2013 Microbiology"
    },
    "K181288.txt": {
        "deviceName": "Athelas One",
        "intendedUse": "Athelas One is indicated for use for quantitative determination of white blood cells (WBC) and Neutrophil percentages (NEUT%) in capillary or K2EDTA venous whole blood.",
        "predicateDevice": "Sysmex XE-5000 Automated Hematology Analyzer",
        "indicationsForUse": "Same as intended use",
        "testPrinciple": "A microfluidic test strip channel creates a stained monolayer of WBCs. Multiple images are taken of the monolayer and the cells are counted and classified by computer vision based image analysis.",
        "analyticalSpecificity": "The interference study results demonstrated that the following interferents do not interfere with test results up to the following concentrations: Triglyceride Rich Lipoproteins 500 mg/dL, Hemolysate 500 mg/dL, Protein 8 g/dL, Levodopa 20 mg/L, Methyldopa 71 \u00b5mol/L, Metronidazole 701 \u00b5mol/L, Acetylsalicyclic Acid 3.62 mmol/L, Phenylbutazone 400 mg/L, Rifampicin 78.1 \u00b5mol/L, Cyclosporine 5 mg/L, Acetaminophen 1324 \u00b5mol/L, Heparin 3000 U/L, Ibuprofen 2425 \u00b5mol/L, Bilirubin C 5 mg/dL, Bilirubin F 15 mg/dL",
        "submissionType": "Clearance of a new device",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The Athelas One is an automated cell counter system which consists of: the Athelas One analyzer and the Athelas One Test Strips.",
        "regulatoryInformation": "21 CFR 864.5220, Automated differential cell counter, Class II, Product code: GKZ, Counter, differential cell"
    },
    "K183462.txt": {
        "deviceName": "Applied Biosystems Bacillus anthracis Detection Kit",
        "intendedUse": "The Applied Biosystems Bacillus anthracis Detection Kit is a real-time polymerase chain reaction (PCR) test kit intended for the qualitative in vitro diagnostic (IVD) detection of target DNA sequences for Bacillus anthracis (B. anthracis, or BA).",
        "predicateDevice": "FilmArray NGDS Warrior Panel",
        "indicationsForUse": "The Applied Biosystems Bacillus anthracis Detection Kit is indicated for use in CLIA-certified high-complexity laboratories in response to a confirmed Bacillus anthracis event only in accordance with the guidelines provided by public health authorities prior to or during a public health emergency.",
        "testPrinciple": "Extraction of whole blood and positive blood culture specimens is performed using a manual Qiagen QIAamp DSP DNA Blood Mini Kit (DSP) extraction method or the automated MagNA Pure (MNP) extraction method. Real-time PCR of the extracted nucleic acids is accomplished with the use of an Applied Biosystems probe, which detects a specific sequence within the region amplified by the assay primers.",
        "analyticalSpecificity": "The Applied Biosystems Bacillus anthracis Detection Kit detects Bacillus anthracis DNA sequences. The kit has been evaluated for potential cross-reactivity with other microorganisms and has demonstrated high analytical specificity.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For Prescription Use Only. Laboratories must maintain records of completed manufacturer required training including training related to use of the assay, instrumentation, biosafety precautions, appropriate PPE and contamination control and waste disposal.",
        "deviceDescription": "The Applied Biosystems Bacillus anthracis Detection Kit is a multiplexed real-time polymerase chain reaction (PCR) test kit intended for the qualitative detection of B. anthracis DNA sequences.",
        "regulatoryInformation": "Class II, Product code: QIF, OOI, Regulation section: CFR 866.4000"
    },
    "K180936.txt": {
        "deviceName": "ETEST Telavancin (TLA)",
        "intendedUse": "ETEST is a quantitative technique for determination of antimicrobial susceptibility of non-fastidious Gram-negative and Gram-positive aerobic bacteria",
        "predicateDevice": "ETEST Ceftaroline",
        "indicationsForUse": "Same as the Intended Use",
        "testPrinciple": "The ETEST consists of a thin, inert, nonporous plastic strip that is used to determine the antimicrobial susceptibility of bacteria",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only. Limitations: Due to the lack of an intermediate category and the observed trending for Telavancin, testing of S. aureus and E. faecalis have resulted in major discrepancies for isolates that are otherwise within essential agreement with the reference method",
        "deviceDescription": "ETEST consists of a thin, inert and non-porous plastic strip 5mm wide and 60 mm long",
        "regulatoryInformation": "Regulation section: 866.1640 Antimicrobial Susceptibility Test Powder, Classification: II, Product code: JWY \u2013 Manual Antimicrobial Test Systems, Panel: 83 \u2013Microbiology"
    },
    "K143329.txt": {
        "deviceName": "AmpliVue Trichomonas Assay",
        "intendedUse": "The AmpliVue Trichomonas Assay is an in vitro diagnostic test, uses isothermal amplification technology (helicase-dependent amplification, HDA) for the qualitative detection of Trichomonas vaginalis nucleic acids isolated from clinician-collected vaginal swab specimens obtained from symptomatic or asymptomatic females to aid in the diagnosis of trichomoniasis.",
        "predicateDevice": "APTIMA Trichomonas vaginalis Assay (PANTHER System)",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "The AmpliVue Trichomonas Assay uses HAD to detect T. vaginalis genomic DNA in vaginal swab specimens.",
        "analyticalSpecificity": "No cross-reactivity was observed with the AmpliVue Trichomonas Assay when testing any of the 45 microorganisms.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The AmpliVue Trichomonas Assay is a self-contained disposable amplicon detection device that uses an isothermal amplification technology named Helicase-Dependent Amplification (HDA) for the detection of Trichomonas vaginalis in clinician-collected vaginal swabs from symptomatic and asymptomatic women.",
        "regulatoryInformation": "21 CFR 866.3860, Class II, Product code: OUY - Trichomonas vaginalis nucleic acid amplification test system, Panel: 83 - Microbiology"
    },
    "K181379.txt": {
        "deviceName": "H. PYLORI QUIK CHEK",
        "intendedUse": "The TECHLAB H. PYLORI QUIK CHEK test is a rapid membrane enzyme immunoassay for the qualitative detection of Helicobacter pylori specific antigen in a single use cassette. It is intended for use with human fecal specimens to aid in the diagnosis of H. pylori infection and to demonstrate loss of H. pylori antigen following treatment.",
        "predicateDevice": "ImmunoCard STAT! HpSA",
        "indicationsForUse": "Same as the Intended Use",
        "testPrinciple": "Lateral flow immunochromatographic assay",
        "analyticalSpecificity": "The H. PYLORI QUIK CHEK test was evaluated for cross-reactivity with the bacteria, fungi, and viruses listed in the document",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The H. PYLORI QUIK CHEK test utilizes antibodies specific for H. pylori antigen in human fecal samples",
        "regulatoryInformation": "21 CFR 866.3110 Campylobacter fetus serological reagents, Class I, Product code: LYR"
    },
    "K190219.txt": {
        "deviceName": "Simplexa VZV Direct",
        "intendedUse": "The DiaSorin Molecular Simplexa VZV Direct assay is intended for use on the LIAISON MDX instrument for the qualitative detection of varicella-zoster virus (VZV) DNA in cerebrospinal fluid (CSF) from patients with signs and/or symptoms of meningitis and/or encephalitis.",
        "predicateDevice": "FilmArray Meningitis/Encephalitis (ME) Panel for use with FilmArray and FilmArray 2.0 systems",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "The Simplexa VZV Direct assay is a real-time polymerase chain reaction (PCR) system that enables the direct amplification and detection of VZV DNA from unprocessed cerebral spinal fluid (CSF) specimens without nucleic acid extraction.",
        "analyticalSpecificity": "The Simplexa VZV Direct assay was evaluated for cross reactivity by testing 105 different bacteria, viruses and fungi which represent closely related organisms or cause similar clinical symptoms. No cross reactivity was observed for the tested organisms at the test concentration indicated.",
        "submissionType": "510(k) Number: K190219",
        "specialConditionsForUse": "Rx - For Prescription Use Only, For in vitro diagnostic use",
        "deviceDescription": "The Simplexa VZV Direct assay is a real-time polymerase chain reaction (PCR) system that enables the direct amplification and detection of VZV DNA from unprocessed cerebral spinal fluid (CSF) specimens without nucleic acid extraction.",
        "regulatoryInformation": "21 CFR 866.3970 - Device to detect and identify microbial pathogen nucleic acids in cerebrospinal fluid, 21 CFR 862.2570 - Instrumentation for clinical multiplex test systems"
    },
    "K151265.txt": {
        "deviceName": "SD GlucoNFC Blood Glucose Meter, SD GlucoNFC Multi Blood Glucose Meter",
        "intendedUse": "The SD GlucoNFC Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood from fingertip, palm, forearm, or upper arm. The SD GlucoNFC Multi Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose (sugar) in fresh capillary whole blood from fingertip, palm, forearm, or upper arm and venous whole blood.",
        "predicateDevice": "SD GlucoMentor BGMS, SD GlucoMentor Multi BGMS",
        "indicationsForUse": "The device is intended for use by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The SD GlucoNFC Multi BGMS is intended for multiple-patient use in professional healthcare settings as an aid to monitor the effectiveness of diabetes control program.",
        "testPrinciple": "The SD GlucoNFC and SD GlucoNFC Multi Blood Glucose Monitoring Systems use an amperometric biosensor technology to measure the glucose level in human blood.",
        "analyticalSpecificity": "The sponsor performed interference studies with spiked venous blood samples at 2 different glucose concentrations (YSI reference values of 65 and 250mg/dL).",
        "submissionType": "New Submission",
        "specialConditionsForUse": "For in vitro diagnostic use. Do not use the system to test neonates. It has not been validated for neonatal use. Critically ill patients should not be tested with this blood glucose meter.",
        "deviceDescription": "The SD GlucoNFC and SD GlucoNFC Multi Blood Glucose Monitoring Systems are over-the-counter and prescription blood glucose monitoring systems, respectively. The devices contain near field communication (NFC) technology.",
        "regulatoryInformation": "Class II, 510(k) Number: K151265, Regulation section: 862.1345, Glucose Test System, 862.1660, Quality control material (assayed and unassayed)"
    },
    "K181700.txt": {
        "deviceName": "HardyDisk AST Plazomicin 30\u00b5g (PLZ30)",
        "intendedUse": "Use of HardyDisk AST Plazomicin 30\u00b5g (PLZ30) for in vitro agar diffusion susceptibility testing is indicated when there is need to determine the susceptibility of bacteria to Plazomicin.",
        "predicateDevice": "HardyDisk Tigecycline 15\u00b5g",
        "indicationsForUse": "Enterobacteriaceae",
        "testPrinciple": "The HardyDisk AST Disk is based on the agar diffusion (Kirby-Bauer) methodology.",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "HardyDisk AST Disks utilize 6-mm diameter white filter paper disks. The disks are prepared by impregnating absorbent paper with a known concentration of 30\u00b5g Plazomicin.",
        "regulatoryInformation": "21 CFR 866.1620 Antimicrobial Susceptibility Test Disc, Class II, Product code: JTN"
    },
    "K171971.txt": {
        "deviceName": "skyla Clinical Chemistry Analyzer, Minicare C300 Clinical Chemistry Analyzer",
        "intendedUse": "The Comprehensive Metabolic Panel is intended to be used for the quantitative determination of Alkaline Phosphate (ALP), Alanine Aminotransferase (ALP/GPT), Aspartate Aminotransferase (AST/GOT), Blood Urea Nitrogen (BUN) and Creatinine (CREA) in concentrations in lithium-heparinized venous whole blood, heparinized plasma, or serum in a clinical laboratory setting or point-of-care location.",
        "predicateDevice": "Abaxis Piccolo, Abaxis Piccolo Primary Health Panel Reagent Rotor",
        "indicationsForUse": "Alkaline phosphatase or its isoenzymes measurements are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases. Alanine aminotransferase measurements are used in the diagnosis and treatment of certain liver diseases (e.g., viral hepatitis and cirrhosis) and heart diseases. Aspartate aminotransferase measurements are used in the diagnosis and treatment of certain types of liver and heart disease. Blood urea nitrogen measurements are used in the diagnosis and treatment of certain types of renal and metabolic diseases. Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.",
        "testPrinciple": "ALP activity is enzymatically determined. p-Nitrophenyl phosphate that is hydrolyzed by ALP into a yellow colored product p-Nitrophenol which has an absorbance at a wavelength of 405 nm. The rate of the reaction is directly proportional to the enzyme activity.",
        "analyticalSpecificity": "The interfering substance with significant interference (>10% bias) are as follows: \u00b7 ALP concentrations are decreased by 14.4% when 4 mg/dL Theophylline is present in the sample. \u00b7 Salicylic Acid at 60 mg/dL causes a 16.3% decrease in ALT levels. \u00b7 Creatinine levels are increased by 11.8% in the presence of 50 mg/dL Ibuprofen.",
        "submissionType": "New Device",
        "specialConditionsForUse": "For prescription use only at point-of-care (POC) and clinical laboratory settings.",
        "deviceDescription": "The Comprehensive Metabolic Panel contains a set of dried reagents that are used in the quantitative testing of various substances in the blood sample.",
        "regulatoryInformation": "Regulation description Product Code Device Class Regulation Number Panel Alkaline Phosphatase test system CJE Class II 862.1050 Clinical Chemistry (75) Blood Urea Nitrogen test system CDN Class II 862.1770 Creatinine test system CGX Class II 862.1225 Aspartate aminotransferase (AST/SGOT) test system CIT Class II 862.1100 Alanine amino transferase (ALT/SGPT) test system CKA Class I 862.1030 Analyzer, chemistry, centrifugal, for clinical use JJG Class I 862.2160"
    },
    "K173829.txt": {
        "deviceName": "NeoLSD MSMS kit",
        "intendedUse": "The NeoLSD MSMS Kit is intended for the quantitative measurement of the activity of the enzymes acid-\u03b2-glucocerebrosidase (ABG), acid-sphingomyelinase (ASM), acid-\u03b1-glucosidase (GAA), \u03b2-galactocerebrosidase (GALC), \u03b1-galactosidase A (GLA), and \u03b1-L-iduronidase (IDUA) in dried blood spots (DBS) from newborn babies.",
        "predicateDevice": "SEEKER System",
        "indicationsForUse": "Gaucher Disease, Niemann-Pick A/B Disease, Pompe Disease, Krabbe Disease, Fabry Disease, and mucopolysaccharidosis Type I (MPS I) Disease",
        "testPrinciple": "The NeoLSD MSMS kit evaluates enzyme activities by measuring the product generated when an enzyme reacts with a synthesized substrate to create a specific end product.",
        "analyticalSpecificity": "The potential interfering substances for possible mass overlaps was assessed by searching two mass spectrometry databases, NIST 14 and MassBank, and CLSI EP07-A2 for potential mass overlaps (\u00b11 Da of the target analytes) of the six enzymatic products and six internal standards.",
        "submissionType": "New device",
        "specialConditionsForUse": "This test is not intended to diagnose lysosomal storage disorders. Test results are intended to be used in conjunction with other clinical and diagnostic findings, consistent with professional standards of practice, including confirmation by alternative methods, and clinical evaluation as appropriate.",
        "deviceDescription": "The NeoLSD MSMS kit consists of substrates, internal standards, and controls. The kit contains sufficient reagents and consumables to perform 960 assays (10 x 96-well plates).",
        "regulatoryInformation": "Regulation section: 862.1488 Lysosomal storage disorder newborn screening test system, Classification: II, Product code: PQW, PQT, PQU, PQV, 2, QCL, QCM"
    },
    "K150168.txt": {
        "deviceName": "Dimension Tacrolimus Flex Reagent Cartridge (TAC)",
        "intendedUse": "For the quantitative measurement of tacrolimus in human whole blood as an aid in the management of tacrolimus therapy in renal and hepatic transplant patients",
        "predicateDevice": "ARCHITECT Tacrolimus Assay",
        "indicationsForUse": "The Dimension Tacrolimus Flex Reagent Cartridge (TAC) is an in vitro diagnostic test for the quantitative measurement of tacrolimus in human whole blood on the Dimension clinical chemistry system. Measurements of tacrolimus are used as an aid in the management of tacrolimus therapy in renal and hepatic transplant patients.",
        "testPrinciple": "The Dimension TAC method is an automated immunoassay in which free and tacrolimus-bound antibody-enzyme conjugate is separated using magnetic particles.",
        "analyticalSpecificity": "The assay has been designed to minimize interference from antibodies to \u00df-galactosidase. In very rare instances, immunoassays may produce falsely elevated or decreased results due to other patient-specific interferents.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "Prescription use only. The instrument reporting system contains flags and comments to provide the user with information regarding instrument processing errors, instrument status information and potential errors in TAC results.",
        "deviceDescription": "The automated Dimension TAC method is performed using a method specific Flex Reagent Cartridge. The reagents for this assay are packaged in an 8-well Flex Reagent Cartridge that contains a pretreatment reagents, antibody-\u00df-galactosidase conjugate, tacrolimus immobilized on chromium dioxide particles, chlorophenol red \u00df-d-galactopyranoside (CPRG) substrate, and diluent to hydrate the tablets.",
        "regulatoryInformation": "21 CFR \u00a7862.1678, Tacrolimus Test System; 21 CFR \u00a7862.1150, Calibrator; Class II; Product code: MLM, JIT"
    },
    "K173817.txt": {
        "deviceName": "Liofilchem MIC Test Strip (MTS), Ceftazidime-avibactam",
        "intendedUse": "The Liofilchem MIC Test Strip (MTS) is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria.",
        "predicateDevice": "Liofilchem MTS, Vancomycin",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "MIC Test Strips (MTS) are made of special high quality paper impregnated with a predefined concentration gradient of antibiotic, across 15 two-fold dilutions like those of a conventional MIC method.",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) Number: K173817",
        "specialConditionsForUse": "For Prescription Use Only, Limitations: \u00b7 Enzyme group characterization was not available for organisms at the time of comparative testing, and therefore the performance of Liofilchem MIC Test Strip Ceftazidime/avibactam MTS for non-fastidious gram negative bacilli is unknown for the following: Enterobacteriaceae (TEM, SHV, CTX-M, KPC, AmpC, and OXA); Pseudomonas aeruginosa (chromosomal AmpC, loss of OprD).",
        "deviceDescription": "The Ceftazidime/avibactam MIC Test Strip (MTS) consists of specialized paper impregnated with a predefined concentration gradient of Ceftazidime/avibactam across 15 two-fold dilutions like those dilutions of a conventional MIC method.",
        "regulatoryInformation": "21 CFR 866.1640 Antimicrobial Susceptibility Test Powder, Class II, Product code(s): JWY \u2013 Manual Antimicrobial Test Systems"
    },
    "K150588.txt": {
        "deviceName": "OVA1 Next Generation",
        "intendedUse": "The OVA1 Next Generation test is a qualitative serum test that combines the results of five immunoassays into a single numeric result. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist.",
        "predicateDevice": "Vermillion OVA1, K081754",
        "indicationsForUse": "Same as Intended use",
        "testPrinciple": "The individual assays for APO and TRF each contain a biomarker specific polyclonal antibody which forms an immune complex with the target when reacted with a serum specimen. The levels of immune complexes can be measured turbidimetrically and are proportional to the concentration of biomarker in the serum specimen for each specific assay.",
        "analyticalSpecificity": "The effect of each interfering substance on the OVA1 Next Generation score was assessed using a mean of four repeated measurements on each sample spiked with the potentially interfering substances and compared to control measurements of samples without the interfering substances but with the same amount of solvent.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The OVA1 Next Generation test consists of software, instruments, assays and reagents. The software incorporates the results of five serum biomarker concentrations from immunoassays run separately to calculate a single, unitless numeric result indicating a low or high risk of ovarian malignancy.",
        "regulatoryInformation": "21 CFR \u00a7866.6050, Ovarian adnexal mass assessment score test system"
    },
    "K193024.txt": {
        "deviceName": "Sensititre 20-24 hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint Susceptibility System with Lefamulin",
        "intendedUse": "in vitro diagnostic product for clinical susceptibility testing of Haemophilus influenzae, Streptococcus pneumoniae, and Streptococcus spp.",
        "predicateDevice": "Sensititre 20-24 hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint Susceptibility System with Omadacycline",
        "indicationsForUse": "The Sensititre 20 - 24 hour Haemophilus influenzae/Streptococcus pneumoniae MIC or Breakpoint Susceptibility System is an in vitro diagnostic product for clinical susceptibility testing of H. influenzae, Streptococcus pneumoniae, and Streptococcus spp.",
        "testPrinciple": "Quantitative Antimicrobial Susceptibility Test (AST), growth-based detection",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "Rx - For Prescription Use Only. The performance of lefamulin with Haemophilus influenzae and Streptococcus pneumoniae was evaluated using the AIM autoinoculator only. The use of an alternative inoculation system when testing lefamulin has not been evaluated.",
        "deviceDescription": "Sensititre MIC Susceptibility MIC panels are multi-well microtiter plates, dosed with dried, stabilized antimicrobials.",
        "regulatoryInformation": "Class II, 21 CFR 866.1640 - Antimicrobial Susceptibility Test Powder, MI - Microbiology"
    },
    "K141114.txt": {
        "deviceName": "BioPlex 2200 25-OH Vitamin D Kit",
        "intendedUse": "For the quantitative determination of 25-hydroxyvitamin D in human serum",
        "predicateDevice": "EUROIMMUN 25-OH Vitamin D ELISA",
        "indicationsForUse": "The BioPlex 2200 25-OH vitamin D assay is to be used to aid in the assessment of vitamin D sufficiency",
        "testPrinciple": "Multiplex flow competitive immunoassay",
        "analyticalSpecificity": "Interference study and cross-reactivity study were performed to measure the effects of endogenous serum components and exogenous molecules on the 25-OH Vitamin D assay",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For in vitro diagnostics, For prescription use only",
        "deviceDescription": "The BioPlex 2200 25-OH Vitamin D Kit consists of the following: One 10mL vial of Bead Set, One 10mL vial of Release Buffer, One 5mL vial of Conjugate 1, One 5mL vial of Conjugate 2",
        "regulatoryInformation": "Product Code: MRG, Classification: II, Regulation Section: 862.1825 Vitamin D Test System"
    },
    "K153683.txt": {
        "deviceName": "Trak Male Fertility Testing System",
        "intendedUse": "semi-quantitative assessment of sperm concentration at 15 million sperm per milliliter (M/mL) or below, between 15 and 55 M/mL, and above 55 M/mL",
        "predicateDevice": "SpermCheck Fertility",
        "indicationsForUse": "same as intended use",
        "testPrinciple": "density gradient separation to isolate sperm cells from human semen",
        "analyticalSpecificity": "evaluated by testing elevated concentrations of saliva, urine, blood, leukocytes, E. coli, C. albicans, C. trachomatis, N. perflava, testosterone, D-norgestrel, and \u03b2-estradiol as interfering substances",
        "submissionType": "510(k) clearance of a new device",
        "specialConditionsForUse": "not applicable",
        "deviceDescription": "includes a small instrument (the Engine), disposable units in which liquefied semen sample is introduced and the result is interpreted (the Prop), and consumables, including collection cups, control solution, and sample droppers",
        "regulatoryInformation": "21 CFR \u00a7 864.5220, Automated differential cell counter, Class II, Product code: GKZ \u2013 Counter, Differential Cell"
    },
    "K161217.txt": {
        "deviceName": "VITEK 2 AST-Gram Negative Ceftriaxone",
        "intendedUse": "The VITEK 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK 2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus spp., S. pneumoniae and clinically significant yeast.",
        "predicateDevice": "VITEK 2 AST-GN Doxycycline",
        "indicationsForUse": "VITEK 2 Gram Negative Ceftriaxone is designed for antimicrobial susceptibility testing of Gram negative bacilli.",
        "testPrinciple": "The VITEK 2 and VITEK 2 Compact Systems utilize automated growth-based detection using attenuation of light measured by an optical scanner.",
        "analyticalSpecificity": "Not Applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "Prescription use only. Perform an alternate method of testing prior to reporting results for the following antibiotic/organism combination: Ceftriaxone/Proteus vulgaris. The ability of the AST card to detect resistance with the following combination(s) is unknown because resistant strains were not available at the time of comparable testing: Ceftriaxone: Shigella species, Providencia rettgeri, and Salmonella species.",
        "deviceDescription": "The VITEK 2 AST card is a miniaturized, abbreviated and automated version of the doubling dilution technique for determining the minimum inhibitory concentration (MIC).",
        "regulatoryInformation": "21 CFR 866.1645 Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System, Class II, Product code: LON, LTW, LTT, Panel: 83 Microbiology"
    },
    "K182353.txt": {
        "deviceName": "EliA CENP Immunoassay, EliA U1RNP Immunoassay, EliA RNP70 Immunoassay",
        "intendedUse": "The EliA CENP is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to CENP in human serum and plasma (Li-heparin, EDTA) as an aid in the clinical diagnosis of scleroderma (CREST Syndrome) in conjunction with other laboratory and clinical findings. EliA U1RNP is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to U1RNP in human serum and plasma (Li-heparin, EDTA) as an aid in the clinical diagnosis of mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE) in conjunction with other laboratory and clinical findings. EliA RNP70 is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to RNP70 in human serum and plasma (Li-heparin, EDTA) as an aid in the clinical diagnosis of mixed connective tissue disease (MCTD) and systemic lupus erythematosus (SLE) in conjunction with other laboratory and clinical findings.",
        "predicateDevice": "EliA CENP on Phadia 250, EliA U1RNP on Phadia 250, EliA RNP70 on Phadia 250",
        "indicationsForUse": "Same as Intended Uses",
        "testPrinciple": "EliA tests are fluorescence immunoassays for the detection and measurement of human antibodies based on EliA solid-phase components, which contain specific antigens for the antibodies to be measured.",
        "analyticalSpecificity": "Interference by endogenous substances was previously reviewed in K082759 (EliA CENP and EliA U1RNP) and K083117 (EliA RNP70). Cross-reactivity was previously reviewed in K082759 (EliA CENP and EliA U1RNP) and K083117 (EliA RNP70).",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "Prescription use only",
        "deviceDescription": "EliA uses a modular reagent system. The assay-specific, method-specific and general reagents are packaged and purchased as separate units.",
        "regulatoryInformation": "21 CFR 866.5100, Antinuclear antibody immunological test system, Class II"
    },
    "K162333.txt": {
        "deviceName": "Wondfo One Step Fecal Occult Blood Test",
        "intendedUse": "The Wondfo One Step Fecal Occult Blood Test is a rapid test for the qualitative detection of human occult blood in feces. It is used as an aid in the diagnosis of gastrointestinal (GI) bleeding.",
        "predicateDevice": "FOB One Step Rapid Test (Orient Gene Biotech)",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "Lateral flow chromatographic immunoassay",
        "analyticalSpecificity": "The ability of Wondfo One Step Fecal Occult Blood (FOB) Test to detect human hemoglobin variants was determined using one kit lot and one operator testing hemoglobin A (HbA), hemoglobin-S (HbS) and hemoglobin-C (HbC).",
        "submissionType": "510(k) clearance of a new device",
        "specialConditionsForUse": "For prescription and over-the-counter (OTC) use.",
        "deviceDescription": "The Wondfo One Step Fecal Occult Blood (FOB) Test kit consists of the following components: a. Test cassette individually wrapped in a single pouch b. Collection tubes with 1.5 mL extraction buffer solution c. Clean collection papers d. Instructions for use",
        "regulatoryInformation": "21 CFR 864.6550, Occult blood test, Class II, Product code: KHE, Reagent, Occult Blood"
    },
    "K180607.txt": {
        "deviceName": "KRONUS Steroid 21-Hydroxylase Autoantibody (21-OHAb) ELISA Kit",
        "intendedUse": "The KRONUS Steroid 21-Hydroxylase Autoantibody (21-OHAb) ELISA Kit is for the qualitative determination of antibodies to steroid 21-hydroxylase (21-OH) in human serum.",
        "predicateDevice": "KRONUS 21-OHAb RIA Assay Kit (K121046)",
        "indicationsForUse": "The KRONUS Steroid 21-Hydroxylase Autoantibody (21-OHAb) ELISA Kit is useful as an aid in the diagnosis of autoimmune adrenal disease, whether expressed as autoimmune Addison's disease (isolated) or Addison's disease as part of the more complex autoimmune polyglandular syndrome (APS), type I or II.",
        "testPrinciple": "The KRONUS Steroid 21-Hydroxylase Autoantibody (21-OHAb) ELISA Kit depends on the divalent properties of the Steroid 21-Hydroxylase autoantibodies (21-OHAb) to form a bridge between 21-OH coated on ELISA plate wells and liquid phase 21-OH-biotin.",
        "analyticalSpecificity": "The KRONUS 21-OHAb ELISA Kit has been evaluated for cross-reactivity with 170 sera from other autoimmune diseases and conditions for autoimmune primary adrenal insufficiency differential diagnosis.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only.",
        "deviceDescription": "The KRONUS Steroid 21-Hydroxylase Autoantibody (21-OHAb) ELISA Kit consists of the following components: Recombinant human 21-OHAb-coated ELISA strip wells, Reference Preparation, Kit Negative Control, Kit Positive Control 1 and 2, 21-OH Reaction Enhancer, 21-OH Biotin, 21-OH Biotin Reconstitution Buffer, Streptavidin Peroxidase (SA-POD), Streptavidin-Peroxidase Diluent, Tetramethylbenzidine Peroxidase Substrate (TMB), Stop solution, Concentrated Wash Solution",
        "regulatoryInformation": "21 CFR \u00a7 866.5660, Multiple autoantibody immunological test system, Class II, Product code: PCG, 21-Hydroxylase Antibody (21-OHAb) antibody assay"
    },
    "K173202.txt": {
        "deviceName": "CP3000 Coagulation Analyzer",
        "intendedUse": "The CP3000 is a fully automated, random-access in vitro blood coagulation analyzer intended for use by healthcare professionals in the clinical laboratory.",
        "predicateDevice": "ACL TOP 700 LAS",
        "indicationsForUse": "Same as Intended Use(s) above",
        "testPrinciple": "Antithrombin concentration is determined by incubating plasma with an excess of bovine Factor-Xa in the presence of heparin.",
        "analyticalSpecificity": "The common endogenous and exogenous interfering substances and their interference results are listed and showed no significant interference up to the indicated concentration for all tested citrated plasma samples.",
        "submissionType": "New device",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The CP3000 is an automated blood coagulation instrument which performs tests for specific parameters in citrated human plasma.",
        "regulatoryInformation": "21 CFR 864.5425, Multipurpose system for in vitro coagulation studies"
    },
    "K163260.txt": {
        "deviceName": "SeptiCyte LAB",
        "intendedUse": "The SeptiCyte LAB is a gene expression assay using reverse transcription polymerase chain reaction to quantify the relative expression levels of host response genes isolated from whole blood collected in the PAXgene Blood RNA Tube.",
        "predicateDevice": "B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S PCT Sensitive KRYPTOR",
        "indicationsForUse": "The SeptiCyte LAB is used in conjunction with clinical assessments and other laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis on their first day of ICU admission.",
        "testPrinciple": "The test employs reverse transcription quantitative PCR (RT-qPCR) to measure relative expression levels of four host response genes (CEACAM4, LAMP1, PLA2G7, and PLAC8) from RNA extracted from the patient whole blood collected in the PAXgene Blood RNA collection tube.",
        "analyticalSpecificity": "The SeptiCyte LAB does not generate a SeptiSCORE when gDNA is used as the sole source of input material for the test.",
        "submissionType": "510(k) Number: K163260",
        "specialConditionsForUse": "Blood must be collected in PAXgene Blood RNA Tube (K042613)",
        "deviceDescription": "The SeptiCyte LAB is an in vitro diagnostic test for simultaneous amplification and detection of four RNA transcripts (LAMP1, CEACAM4, PLA2G7, PLAC8) using total RNA extracted from human blood.",
        "regulatoryInformation": "Regulation section: 21 CFR 866.3215; Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis"
    },
    "K141689.txt": {
        "deviceName": "FastPack High Sensitivity C-Reactive Protein Immunoassay",
        "intendedUse": "For in-vitro diagnostic use in evaluating conditions thought to be associated with inflammation, in otherwise healthy individuals",
        "predicateDevice": "Olympus CRP Latex Reagent",
        "indicationsForUse": "Evaluation of conditions thought to be associated with inflammation, in otherwise healthy individuals",
        "testPrinciple": "Sandwich immunoassay principle using murine monoclonal anti-CRP antibodies",
        "analyticalSpecificity": "No significant interference found with endogenous substances such as bilirubin, hemoglobin, lipids, albumin, rheumatoid factor, transferrin, human anti-mouse IgG HAMA, and heterophile/HAMA",
        "submissionType": "510(k) submission",
        "specialConditionsForUse": "For prescription use only, for in vitro diagnostic use only, not intended for Point-of-Care use",
        "deviceDescription": "A paramagnetic particle, chemiluminescent immunoassay employing specific murine monoclonal antibodies",
        "regulatoryInformation": "Class II, regulated under 21 CFR 866.5270, 21 CFR 862.1150, and 21 CFR 862.1660"
    },
    "K182513.txt": {
        "deviceName": "FluChip-8G Influenza A+B Assay",
        "intendedUse": "The FluChip-8G Influenza A+B Assay is a multiplex RT-PCR in vitro diagnostic test intended for the qualitative detection and differentiation of seasonal influenza A/H3N2, seasonal influenza A/H1N1pdm09, and \u201cnon-seasonal\u201d influenza A subtypes other than seasonal H1N1pdm09 or H3N2. The assay is also intended for the qualitative detection and differentiation of the genetic lineage of human influenza B viruses as B/Victoria or B/Yamagata.",
        "predicateDevice": "CDC Human Influenza Virus Real-Time PCR Diagnostic Panel",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "The FluChip-8G Influenza A+B Assay includes a multiplex primer mix to amplify the hemagglutinin (HA), neuraminidase (NA), matrix (M), non-structural (NS), and nucleoprotein (NP) gene segments of all influenza A viruses, as well as the hemagglutinin (HA) and neuraminidase (NA) gene segments of all influenza B viruses, and a portion of the 18s gene present in eukaryotic cells as an endogenous internal control.",
        "analyticalSpecificity": "Analytical specificity for all target virus groups was evaluated with the FC8G assay to determine whether strains of a known target influenza virus group were misidentified as another influenza virus group targeted by the assay when run at high concentration.",
        "submissionType": "510(k) submission",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The FluChip-8G Influenza A+B Assay system is a molecular assay system for the detection and differentiation of influenza viruses in which a multiplexed one-step RT-PCR amplification is coupled with downstream microarray-based hybridization, imaging, and subsequent influenza virus detection and characterization using a pattern recognition-based algorithm.",
        "regulatoryInformation": "The FluChip-8G Influenza A+B Assay is classified as a Class II device."
    },
    "K161258.txt": {
        "deviceName": "NOVA Lite DAPI ANCA (Ethanol) Kit and NOVA Lite DAPI ANCA (Formalin) Kit",
        "intendedUse": "The presence of ANCA, in conjunction with other serological, radiological, histological, and clinical findings, aids in the diagnosis of ANCA associated vasculitides.",
        "predicateDevice": "NOVA Lite ANCA",
        "indicationsForUse": "Same as intended use",
        "testPrinciple": "Samples are diluted 1:20 in PBS and incubated with the antigen substrate (human neutrophil granulocytes fixed on glass microscope slides).",
        "analyticalSpecificity": "No interference was detected with the tested substances, up to the maximal concentrations indicated above.",
        "submissionType": "510(k) Number: K161258",
        "specialConditionsForUse": "For prescription use only. The device is for use by a trained operator in a clinical laboratory setting.",
        "deviceDescription": "NOVA Lite DAPI ANCA (Ethanol) and DAPI ANCA (Formalin) Kits are indirect immunofluorescence assays for the qualitative detection and semi-quantitative determination of anti-neutrophil cytoplasmic antibodies of IgG isotypes in human serum.",
        "regulatoryInformation": "21 CFR \u00a7866.5660, Multiple autoantibodies immunological test system"
    },
    "K161619.txt": {
        "deviceName": "Xpert TV Assay",
        "intendedUse": "The Cepheid Xpert TV Assay, performed on the GeneXpert Instrument Systems, is a qualitative in vitro diagnostic test for the detection of Trichomonas vaginalis genomic DNA.",
        "predicateDevice": "Cepheid Xpert TV Assay (K151565)",
        "indicationsForUse": "The Xpert TV Assay is intended to aid in the diagnosis of trichomoniasis in symptomatic or asymptomatic individuals.",
        "testPrinciple": "This assay detects and amplifies Trichomonas vaginalis genomic DNA using real time polymerase chain reaction technology.",
        "analyticalSpecificity": "Inclusivity, microbial interference (cross-reactivity) and carryover/cross contamination studies were previously reviewed and described in K151565.",
        "submissionType": "510(k) submission",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The Xpert TV Assay is an automated real-time polymerase chain reaction (PCR) in vitro diagnostic test for the qualitative detection of genomic DNA from Trichomonas vaginalis.",
        "regulatoryInformation": "21 CFR 866.3860, Trichomonas vaginalis nucleic acid assay, Class II"
    },
    "K150526.txt": {
        "deviceName": "Optilite IgG4 Kit",
        "intendedUse": "The Optilite IgG4 kit is intended for the quantitative in vitro measurement of IgG4 in serum using the Binding Site Optilite analyser.",
        "predicateDevice": "Binding Site Human IgG and IgG subclass (IgG1, IgG2, IgG3, IgG4) liquid reagent kits for use on the SPAplus",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "The determination of soluble antigen concentration by turbidimetric methods involves the reaction with specific antiserum to form insoluble complexes.",
        "analyticalSpecificity": "Interference:  Interferences were assessed according to CLSI EP7-A2 by testing five serum samples with different IgG4 concentration ranges",
        "submissionType": "New Device",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The device consists of the following: polyclonal monospecific sheep anti-IgG4 antisera coated onto polystyrene latex in liquid form in the presence of preservatives; IgG4 calibrator and Controls (Low, High and Elevated levels) in stabilized liquid form with preservatives; and Reaction Buffer (with 0.099% sodium azide as preservative).",
        "regulatoryInformation": "21 CFR \u00a7866.5510 - Immunoglobulins A, G, M, D, E Immunological Test System"
    },
    "K171974.txt": {
        "deviceName": "Solana RSV+hMPV Assay",
        "intendedUse": "The Solana RSV+hMPV Assay is a qualitative in vitro diagnostic test for the detection and differentiation of RSV and hMPV viral RNA in nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection.",
        "predicateDevice": "Lyra RSV+hMPV Assay",
        "indicationsForUse": "As a diagnostic aid in patients with signs and symptoms of respiratory infection.",
        "testPrinciple": "The assay consists of two major steps: 1) specimen preparation, and 2) amplification and detection of target sequences specific to RSV and/or hMPV using isothermal Reverse Transcriptase - Helicase-Dependent Amplification (RT-HDA) in the presence of target-specific fluorescence probes.",
        "analyticalSpecificity": "The Solana RSV+hMPV Assay was evaluated for potential cross-reactivity (false positive results) with organisms that may be found in the nasal passages of patients with symptoms of respiratory tract infection. No cross-reactivity was observed with the organisms tested at the concentrations tested.",
        "submissionType": "New device; to obtain market clearance for the Solana RSV+hMPV Assay when performed on the Solana instrument.",
        "specialConditionsForUse": "\u00b7 For in vitro diagnostic use only \u00b7 For prescription use only",
        "deviceDescription": "An aliquot (50 \u03bcL) of patient nasal or nasopharyngeal swab specimen collected in viral transport media is transferred to a Process Buffer Tube. One Process Buffer Tube, which contains a competitive process control (PRC), is required for each specimen or control sample to be tested.",
        "regulatoryInformation": "Class II, 21 CFR 866.3980 Respiratory viral panel multiplex nucleic acid assay"
    },
    "K160585.txt": {
        "deviceName": "XN CAL",
        "intendedUse": "XN CAL is used for the calibration and calibration verification of Sysmex XN series (XN-10, XN-11, XN-20, XN-21, XN-L) analyzers",
        "predicateDevice": "XN CAL",
        "indicationsForUse": "Same as intended use",
        "testPrinciple": "XN CAL was designed to function as a substitute for fresh whole blood to calibrate the Sysmex XN10/20, XN 11/21, and XN-L series hematology analyzers",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "XN CAL is an in-vitro diagnostic product that contains the following: stabilized red blood cell component(s), stabilized white blood cell component(s), stabilized platelet component(s), and stabilized nucleated red blood cell component(s) in a preservative medium",
        "regulatoryInformation": "21 CFR \u00a7 864.8150, Calibrator for cell indices"
    },
    "K180209.txt": {
        "deviceName": "Diazyme 1,5-AG Assay",
        "intendedUse": "The Diazyme 1,5-anhydroglucitol (1,5-AG) Assay is an enzymatic method intended for the quantitative determination of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The 1,5-AG Assay is for the intermediate term (preceding 1-2 weeks) monitoring of glycemic control in people with diabetes.",
        "predicateDevice": "GlycoMark",
        "indicationsForUse": "The intermediate term monitoring of glycemic control in people with diabetes",
        "testPrinciple": "The enzyme pyranose oxidase (PROD) to oxidize the 2nd position hydroxyl group of 1,5-AG and to detect the generated hydrogen peroxide by colorimetry using peroxidase (POD)",
        "analyticalSpecificity": "Interference studies were conducted with serum samples adjusted to three levels of 1,5-AG. The following substances were tested up to the levels indicated and demonstrated no significant interference: Bilirubin, Conjugated Bilirubin, Hemoglobin, Triglycerides, Ascorbic Acid, Glucose, Maltose, Uric Acid, Creatinine, Urea",
        "submissionType": "New Device",
        "specialConditionsForUse": "For in vitro diagnostic use only, Prescription use only",
        "deviceDescription": "Diazyme\u2019s 1,5-AG Assay is an enzymatic method consisting of a two-reagent test kit (Reagent 1 and Reagent 2) and is to be used with a fully automated chemistry analyzer",
        "regulatoryInformation": "21 CFR 864.7470; Glycosylated hemoglobin assay, Class II, Product code: NOZ; Assay, 1,5-Anhydroglucitol, Panel: Hematology (81)"
    },
    "K143502.txt": {
        "deviceName": "Immunalysis Opiates Urine Enzyme Immunoassay",
        "intendedUse": "For the qualitative and semi-quantitative analysis of opiates in human urine",
        "predicateDevice": "DRI DAU Opiate Assay",
        "indicationsForUse": "The assay is intended for use in laboratories for the qualitative and semi-quantitative analysis of opiates in human urine with automated clinical chemistry analyzers",
        "testPrinciple": "The assay is based on the competition of opiates labeled enzyme glucose-6-phosphate dehydrogenase (G6PDH) and the free drug in the urine sample for the fixed amount of antibody binding sites",
        "analyticalSpecificity": "The assay has been evaluated for potential interference from non-structurally and structurally related compounds",
        "submissionType": "510(k) Premarket Notification",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The Immunalysis Opiates Urine Enzyme Immunoassay Kit contains two reagents, which are provided as ready-to-use",
        "regulatoryInformation": "Product Code: DJG, Classification: II, Regulation Section: 862.3650"
    },
    "K163626.txt": {
        "deviceName": "ARIES Bordetella Assay",
        "intendedUse": "The ARIES Bordetella Assay is a real-time polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection and identification of Bordetella pertussis (B. pertussis) and Bordetella parapertussis (B. parapertussis) nucleic acid in nasopharyngeal swab (NPS) specimens obtained from individuals suspected of having a respiratory tract infection attributable to B. pertussis or B. parapertussis.",
        "predicateDevice": "illumigene Pertussis DNA Amplification Assay (Meridian Bioscience, Inc.)",
        "indicationsForUse": "Same as intended use",
        "testPrinciple": "The ARIES Bordetella Assay chemistry is based on an expanded genetic alphabet technology, consisting of synthetic DNA base pair\u20142'-deoxy-5-methyl-isocytidine (iC):2'-deoxyisoguanosine (iG).",
        "analyticalSpecificity": "The ability of the ARIES Bordetella Assay to detect multiple strains of B. pertussis and B. parapertussis was evaluated in analytical reactivity (inclusivity) studies.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The ARIES Bordetella Assay is a polymerase chain reaction (PCR)-based qualitative in vitro diagnostic test system that consists of the ARIES System or the ARIES M1 System with their included ARIES Software, an assay-specific cassette, and an assay-specific protocol file.",
        "regulatoryInformation": "Class II, Product code: OZZ, Regulation section: 866.3980 Respiratory viral panel multiplex nucleic acid assay"
    },
    "K173505.txt": {
        "deviceName": "FORA GTel Blood Glucose Monitoring System",
        "intendedUse": "The FORA GTel Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertip. It is intended for in vitro diagnostic use by people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program.",
        "predicateDevice": "FORA GD43 Blood Glucose Monitoring System",
        "indicationsForUse": "The FORA GTel Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertip. It is intended for in vitro diagnostic use by people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program.",
        "testPrinciple": "The system measures the amount of sugar (glucose) in whole blood. The glucose testing is based on the measurement of electrical current generated by the reaction of glucose with the reagent of the strip.",
        "analyticalSpecificity": "Potential interfering substances were evaluated at three glucose concentration intervals (61, 119, and 264 mg/dL) by analyzing 39 potentially interfering exogenous and endogenous substances.",
        "submissionType": "510(k) Number: K173505",
        "specialConditionsForUse": "For in vitro diagnostic use (for use outside of the body only). This system should not be used for the diagnosis of, or screening for diabetes. For single-patient use only. This system is not for use on patients with abnormally low blood pressure. Inaccurate results may occur in severely hypotensive individuals or patients in shock.",
        "deviceDescription": "The FORA GTel Blood Glucose Monitoring System consists of the FORA GTel Blood Glucose Meter, Owner\u2019s Manual, Protective Wallet, Quick Start User Guide, Daily Log Book, Warranty Card and 1 x Li-ion rechargeable batteries.",
        "regulatoryInformation": "21 CFR 862.1345, Glucose test system, Class II, Product code: NBW, System Test, Blood Glucose, Over the Counter"
    },
    "K182357.txt": {
        "deviceName": "HardyDisk AST Eravacycline 20\u00b5g (ERV20)",
        "intendedUse": "For semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens",
        "predicateDevice": "HardyDisk Tigecycline 15\u00b5g",
        "indicationsForUse": "Use of HardyDisk AST Eravacycline 20\u00b5g (ERV20) for in vitro agar diffusion susceptibility testing is indicated when there is need to determine the susceptibility of bacteria among the Enterobacteriaceae to Eravacyline",
        "testPrinciple": "The HardyDisk AST Disk is based on the agar diffusion (Kirby-Bauer) methodology",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "HardyDisk AST Disks utilize 6-mm diameter white filter paper disks. The disks are prepared by impregnating absorbent paper with a known concentration of 20\u00b5g Eravacycline",
        "regulatoryInformation": "21 CFR 866.1620 Antimicrobial Susceptibility Test Disc, Class II, Product code: JTN"
    },
    "K143075.txt": {
        "deviceName": "ST AIA-PACK SHBG",
        "intendedUse": "For the quantitative measurement of sex hormone binding globulin (SHBG) in human serum or Na heparinized plasma on Tosoh AIA System Analyzers",
        "predicateDevice": "Architect SHBG Reagent Kit",
        "indicationsForUse": "The ST AIA-PACK SHBG assay is intended for use as an aid in the diagnosis of androgen disorders",
        "testPrinciple": "The ST AIA-PACK SHBG is a two-site immunoenzymometric assay",
        "analyticalSpecificity": "Cross reactivity to structurally similar endogenous steroids with the ST AIA-PACK SHBG assay was determined by spiking human serum samples with each compound",
        "submissionType": "New Device",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The ST AIA-PACK SHBG consists of 5 trays of 20 test cups which contain twelve lyophilized magnetic beads coated with anti-SHBG mouse monoclonal antibody",
        "regulatoryInformation": "Class I, reserved, 21 CFR 862.1680, Clinical Chemistry (75)"
    },
    "K150815.txt": {
        "deviceName": "BD FACSPresto System",
        "intendedUse": "For use with the BD FACSPresto CD4/Hb Cartridge and BD FACSPresto CD4/Hb Cartridge Kit in the direct quantification and enumeration of CD4 absolute count, CD4 of lymphocyte, and determination of hemoglobin concentration in normal and HIV positive patients in conjunction with other laboratory and clinical findings.",
        "predicateDevice": "BD FACSCalibur using BD Tritest CD3/CD4/ CD45 with BD Trucount Tubes",
        "indicationsForUse": "For use in children, adolescents, and adults. For use with human whole blood from fingerstick and/or venous collections in K2 EDTA or K3 EDTA blood collection tubes. Not for point-of-care use. For in vitro diagnostic use.",
        "testPrinciple": "The BD FACSPresto instrument is an automated multicolor fluorescent imaging cytometer and absorbance spectrometer with camera, light-emitting diode (LED) illumination, touchscreen user-interface, battery backup power, and onboard software algorithms that analyze images and report results.",
        "analyticalSpecificity": "The endogenous and exogenous interference studies were performed in accordance with CLSI EP07-A2 guidelines.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For Prescription Use Only",
        "deviceDescription": "The device consists of the BD FACSPresto system, the BD FACSPresto CD4/Hb Cartridge, and the BD FACSPresto CD4/Hb Cartridge Kit.",
        "regulatoryInformation": "21 CFR \u00a7864.5220, Automated Differential Cell Counter, 21 CFR \u00a7864.8625, Hematology Quality Control Mixture"
    },
    "K152386.txt": {
        "deviceName": "NxTAG Respiratory Pathogen Panel",
        "intendedUse": "The NxTAG Respiratory Pathogen Panel is a qualitative test intended for use on the Luminex MAGPIX Instrument for the simultaneous detection and identification of nucleic acids from multiple respiratory viruses and bacteria extracted from nasopharyngeal swabs collected from individuals with clinical signs and symptoms of a respiratory tract infection.",
        "predicateDevice": "BioFire Diagnostics, LLC FilmArray Respiratory Panel",
        "indicationsForUse": "The test is indicated as an aid in the detection and identification of viral and bacterial agents causing respiratory tract infections in symptomatic adult and pediatric patients, who are either hospitalized, admitted to emergency departments or who are outpatients with suspected respiratory tract infection.",
        "testPrinciple": "The NxTAG RPP Assay utilizes automated real-time reverse-transcription polymerase chain reaction (RT-PCR) for unique gene-specific sequence amplification and hybridization of labeled probes to magnetic beads for sorting and detection.",
        "analyticalSpecificity": "The analytical reactivity of the NxTAG RPP Assay was evaluated against multiple strains of each analyte detected by the assay.",
        "submissionType": "510(k) submission",
        "specialConditionsForUse": "Prescription use only",
        "deviceDescription": "The NxTAG Respiratory Pathogen Panel (RPP) is a qualitative test intended for the simultaneous detection and identification of nucleic acids from multiple respiratory viruses and bacteria extracted from nasopharyngeal swabs collected from individuals with clinical signs and symptoms of respiratory tract infection.",
        "regulatoryInformation": "The NxTAG RPP Assay is regulated under 21 CFR 866.3980, Respiratory viral panel multiplex nucleic acid assay"
    },
    "K170293.txt": {
        "deviceName": "Emit II Plus Cocaine Metabolite Assay",
        "intendedUse": "The Emit II Plus Cocaine Metabolite Assay is intended for use in the qualitative and semiquantitative analyses of benzoylecgonine (cocaine metabolite) in human urine.",
        "predicateDevice": "Emit II Plus Cocaine Metabolite Assay",
        "indicationsForUse": "For the qualitative and semiquantitative determination of the presence of benzoylecgonine in human urine",
        "testPrinciple": "The Emit II Plus Cocaine Metabolite Assay is based on competition between free drug in the specimen and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH), for antibody binding sites.",
        "analyticalSpecificity": "The assay has significant cross reactivity with benzoylecgonine glucuronide, a metabolite of benzoylecgonine.",
        "submissionType": "510(k)",
        "specialConditionsForUse": "For Prescription use only",
        "deviceDescription": "The Emit II Plus Cocaine Metabolite Assay consists of two ready-to-use reagents: Antibody/Substrate Reagent 1 and Enzyme Reagent 2",
        "regulatoryInformation": "Class II, 21 CFR 862.3250, Product Code: DIO"
    },
    "K182922.txt": {
        "deviceName": "Liofilchem MTS Omadacycline 0.002-32 \u03bcg/mL",
        "intendedUse": "The Liofilchem MTS (MIC Test Strip) Omadacycline 0.002-32 \u03bcg/mL is a quantitative method intended for the in vitro determination of antimicrobial susceptibility of bacteria.",
        "predicateDevice": "Liofilchem MTS, vancomycin",
        "indicationsForUse": "Same as Intended Use",
        "testPrinciple": "MTS are made of specialized paper impregnated with a predefined concentration gradient of antibiotic, across 15 two-fold dilutions similar to dilutions used by conventional MIC methods.",
        "analyticalSpecificity": "Not Applicable",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For prescription use; Resistance mechanism characterization was not available for all organisms at the time of comparative testing, and therefore the performance of the MTS Omadacycline for non-fastidious gram-negative bacilli and gram-positive cocci is unknown for the following: Enterobacteriaceae [tet(B)]; Enterococcus species [tet(K), tet(L)]; S. aureus [tet(L)]",
        "deviceDescription": "The Omadacycline MIC Test Strip (MTS) consists of specialized paper impregnated with a predefined concentration gradient of omadacycline across 15 two-fold dilutions similar to dilutions used by conventional MIC methods.",
        "regulatoryInformation": "Regulation section: 866.1640 Antimicrobial Susceptibility Test Powder; Classification: II; Product code: JWY - Manual Antimicrobial Susceptibility Test Systems; Panel: 83 \u2013 Microbiology"
    },
    "K150281.txt": {
        "deviceName": "Nova StatStrip Glucose Hospital Meter System",
        "intendedUse": "The StatStrip Glucose Hospital Meter System is intended for point-of-care, in vitro diagnostic, multiple-patient use for the quantitative determination of glucose in capillary finger stick, venous whole blood, arterial whole blood, neonate arterial whole blood and neonate heel stick specimens.",
        "predicateDevice": "Nova StatStrip Glucose Hospital Meter System",
        "indicationsForUse": "The StatStrip Glucose Hospital Meter System is intended for the quantitative determination of glucose in capillary finger stick, venous whole blood, arterial whole blood, neonate arterial whole blood and neonate heel stick specimens.",
        "testPrinciple": "The Nova StatStrip Hospital Meter System is based on electrochemical biosensor technology and the principle of capillary action. The system quantitatively measures blood glucose levels using glucose oxidase enzyme chemistry.",
        "analyticalSpecificity": "Potential interference from common endogenous and exogenous substances, as well as in vivo interference, was evaluated in k060345 and k132121.",
        "submissionType": "Modified device to add wireless (Wi-Fi) connectivity, modify the meter layout and revise the accompanying docking/charging station.",
        "specialConditionsForUse": "For prescription use only, For in vitro diagnostic use only, Capillary whole blood specimens should not be used in patients receiving intensive medical intervention/therapy because of the potential for pre-analytical collection error and specifically in patients with decreased peripheral blood flow.",
        "deviceDescription": "The modified system consists of the StatStrip Glucose Hospital meter (with integrated Wi-Fi connection and antenna option), StatStrip Test Strips, Nova StatStrip Control Solutions, Nova StatStrip Linearity Test Kit solutions, charging station, battery, Quick Reference Guide, and User Manual.",
        "regulatoryInformation": "21 CFR 862.1345, Glucose test system, Class II, Product code: CGA, Glucose Oxidase, Glucose, Panel: Clinical Chemistry (75)"
    },
    "K161831.txt": {
        "deviceName": "IDS-iSYS 25VitDS",
        "intendedUse": "For in vitro diagnostic use only. For prescription use only.",
        "predicateDevice": "IDS-iSYS 25-Hydroxy Vitamin DS Assay",
        "indicationsForUse": "The IDS-iSYS 25 VitDS  Assay is intended for the quantitative determination  of  total   25-hydroxyvitamin  D  [(25(OH)D]  in human  serum  or  plasma  on  the  IDS-iSYS   Multi-Discipline Automated System. Results are to be used in conjunction with other  clinical and laboratory data to assist the clinician in the assessment of vitamin D  sufficiency in an adult population.",
        "testPrinciple": "The assay is based on chemiluminescence technology.",
        "analyticalSpecificity": "The IDS-iSYS 25VitDS assay has been tested for interference from common or known substances that could interfere with the assay, including bilirubin, hemoglobin, triglycerides, and rheumatoid factor.",
        "submissionType": "510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION",
        "specialConditionsForUse": "For in vitro diagnostic use only. For prescription use only.",
        "deviceDescription": "The IDS-iSYS 25VitDS assay consists of a reagent cartridge (with multiple components) and one set of calibrators.",
        "regulatoryInformation": "Class II, 21 CFR 862.1825, Vitamin D Test System, 21 CFR 862.1660, Quality Control Material"
    },
    "K172287.txt": {
        "deviceName": "QIAGEN ipsogen JAK2 RGQ PCR Kit",
        "intendedUse": "The ipsogen JAK2 RGQ PCR Kit is a qualitative in vitro diagnostic test for the detection of the JAK2 V617F/G1849T allele in genomic DNA extracted from EDTA whole blood.",
        "predicateDevice": "ipsogen JAK2 RGQ PCR Kit",
        "indicationsForUse": "The test is intended for use as an adjunct to evaluation of suspected myeloproliferative neoplasms, in conjunction with other clinicopathological factors.",
        "testPrinciple": "Allele-specific, quantitative, polymerase chain reaction (PCR) using an amplification refractory mutation system (ARMS)",
        "analyticalSpecificity": "The assay reports the JAK2 percentage because the additional information on potential mutant allele burden enhances diagnostic evaluation",
        "submissionType": "Expansion of the Indications for Use",
        "specialConditionsForUse": "For prescription use only. For in vitro diagnostic use only.",
        "deviceDescription": "The ipsogen JAK2 RGQ PCR Kit employs allele-specific, quantitative, polymerase chain reaction (PCR) using an amplification refractory mutation system (ARMS).",
        "regulatoryInformation": "Class II, 21 CFR 866.6070, Product code: PSU, Panel: 88 \u2013 Pathology"
    },
    "K170974.txt": {
        "deviceName": "BD FACSLyric Flow Cytometer",
        "intendedUse": "The BD FACSLyric flow cytometer is intended for use as an in vitro diagnostic device for immunophenotyping using up to six fluorescence detection channels and two light scatter channels using a blue (488-nm) and a red (640-nm) laser.",
        "predicateDevice": "BD FACSCanto II",
        "indicationsForUse": "These reagents are indicated for use in the immunological assessment of normal individuals, and patients having, or suspected of having, immune deficiency.",
        "testPrinciple": "Flow cytometers combine fluidics, optics, and electronics subsystems to measure and analyze signals emitted when particles in a liquid stream flow through a glass cuvette at which beams of laser light are directed.",
        "analyticalSpecificity": "Not applicable",
        "submissionType": "New device",
        "specialConditionsForUse": "For Prescription Use Only",
        "deviceDescription": "The BD FACSLyric flow cytometer systems consist of a flow cytometer, sheath tank, waste tank, and a computer workstation.",
        "regulatoryInformation": "Class II, 21 CFR 864.5220, Automated Differential Cell Counter"
    },
    "K151917.txt": {
        "deviceName": "Luminex ARIES System",
        "intendedUse": "The Luminex ARIES System is an in vitro diagnostic (IVD) platform that performs nucleic acid based tests in clinical laboratories",
        "predicateDevice": "BD MAX System",
        "indicationsForUse": "The Luminex ARIES System is capable of automated extraction and purification of nucleic acids from multiple sample types as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR",
        "testPrinciple": "Real Time PCR",
        "analyticalSpecificity": "Not explicitly stated in the document, but referenced to k151906 for details",
        "submissionType": "510(k) submission",
        "specialConditionsForUse": "For prescription use only",
        "deviceDescription": "The ARIES System is a clinical multiplex test system that automates and integrates extraction of nucleic acid from a clinical sample, performs real-time PCR, and measuring and sorting multiple signals generated in an in vitro diagnostic assay",
        "regulatoryInformation": "Class II (special controls), 21 CFR 862.2570 Instrumentation for clinical multiplex test systems"
    },
    "K162526.txt": {
        "deviceName": "Creatine Kinase-MB",
        "intendedUse": "The Creatine Kinase-MB assay is an in vitro test for the quantitative determination of the catalytic activity of creatine kinase MB subunit (CK-MB) in human serum and plasma on Roche/Hitachi cobas c systems.",
        "predicateDevice": "Roche CK-MB",
        "indicationsForUse": "Measurements of creatine phosphokinase and its isoenzymes are used in the diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy.",
        "testPrinciple": "Creatine kinase (CK) catalyzes the dephosphorylation of creatine phosphate, generating ATP from ADP. Glucose is then phosphorylated by the ATP formed in the previous reaction to form D-glucose-6-phosphate (G6P), a process catalyzed by hexokinase (HK).",
        "analyticalSpecificity": "The effects of interference by hemoglobin, lipemia (Intralipid), and bilirubin on the CK-MB test system was determined on the cobas c 501 analyzer using pooled human serum samples with 2 CK-MB levels.",
        "submissionType": "New device",
        "specialConditionsForUse": "For prescription use only.",
        "deviceDescription": "The Creatine Kinase-MB assay consists of two reagents: R1 Imidazole buffer and R2 CAPSO buffer.",
        "regulatoryInformation": "21 CFR 862.1215, Creatine phosphokinase/creatine kinase or isoenzymes test system, Class II, Product code: JHW, U.V. Method, Cpk Isoenzymes"
    },
    "K193393.txt": {
        "deviceName": "BOND Ready-to-Use Primary Antibody Progesterone Receptor (16), Novocastra Liquid Mouse Monoclonal Antibody Progesterone Receptor Clone 16",
        "intendedUse": "For in vitro diagnostic use. BOND Ready-to-Use Primary Antibody Progesterone Receptor (16) is a monoclonal antibody intended to be used for the qualitative identification by light microscopy of human progesterone receptor in formalin-fixed, paraffin-embedded tissue by immunohistochemical staining using the automated BOND-MAX or BOND-III systems.",
        "predicateDevice": "BOND Ready-to-Use Primary Antibody Progesterone Receptor (16), Novocastra Liquid Mouse Monoclonal Antibody Progesterone Receptor Clone 16 (K171753)",
        "indicationsForUse": "Progesterone Receptor Clone (16) is indicated as an aid in the management, prognosis and prediction of therapy outcome of breast cancer.",
        "testPrinciple": "Immunohistochemical techniques are used to demonstrate the presence of antigens in tissue and cells.",
        "analyticalSpecificity": "Analytical specificity and interference studies were provided in the original 510k notification.",
        "submissionType": "Traditional 510(k) notification",
        "specialConditionsForUse": "Rx - For Prescription Use Only",
        "deviceDescription": "BOND Ready-to-Use Primary Antibody Progesterone Receptor (16), Novocastra Liquid Mouse Monoclonal Antibody Progesterone Receptor Clone 16 (Concentrated Liquid Antibody Format)",
        "regulatoryInformation": "Class II, 21 CFR 864.1860 - Immunohistochemistry Reagents and Kits"
    }
}